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Quality of life. 
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i 
ABSTRACT 
Chronic lymphocytic leukemia (CLL) is still regarded as an incurable disease with a great 
need for developing new therapies and optimizing existing treatment options. The 
development of targeted therapy, i.e. therapy interfering with specific molecules needed for 
carcinogenesis and tumor growth, is rapidly evolving. The aim of this thesis is to delineate 
the clinical and immunological effects of targeted therapy with alemtuzumab in CLL patients. 
In the first study, a long-term follow-up of patients who received alemtuzumab as first-line 
therapy was conducted. The results were compared with matched historic controls. Median time 
to treatment failure (TTTF) was 28 months for the alemtuzumab treated compared with 17 
months for the control group (not significant). Additionally, our data showed that, despite long-
lasting T cell suppression, alemtuzumab treated patients had comparable rates of infectious 
complications and incidence of Richter transformation as the matched controls. 
In the second study, patients with advanced CLL, who all had severe transfusion-dependent and 
multi-agent refractory autoimmune hemolytic anemia (AIHA), received alemtuzumab as 
salvage therapy. All patients responded with a ≥ 2.0 g/dl rise in hemoglobin (Hb) concentration, 
in the absence of further transfusions, after a median time of 5 weeks. No further AIHA 
episodes were observed during long-term follow-up. CLL responses were achieved in all but 
one patient. These results suggest that alemtuzumab may be effective in the treatment of severe 
AIHA in patients with progressive CLL who have failed to respond to conventional therapy. 
In the third study, the type, severity and duration of side-effects as well as efficacy of 
subcutaneous (SC) alemtuzumab, without dose-escalation, was evaluated in advanced-stage 
relapsed CLL patients. A starting dose of 30 mg SC was well tolerated and all but one injection-
site reactions were grade 1/2. A 75% overall response rate (ORR) and long TTTF (median 20 
months for responding patients) was obtained, suggesting that optimal selection of advanced-
phase CLL patients for alemtuzumab therapy may result in a high response rate and durable 
remissions.  
In the fourth study, T cell receptor B-variable (TCR-BV) gene usage in CD4 and CD8 T cells 
was assessed by real-time PCR, as well as complementarity-determining region 3 (CDR3)-
length polymorphism, before and after therapy in patients with CLL who received 
alemtuzumab as first-line therapy. Our results indicate that perturbations of the T cell repertoire 
following alemtuzumab are complex and not reflected by changes in the total number of 
CD4/CD8 T cells only. A restricted CDR3 pattern present prior to therapy became even more 
restricted after treatment, followed by a normalisation of CD4 repertoire during long-term 
follow-up. 
In the fifth study, we investigated the incidence and clinical relevance of subclinical virus 
reactivations and serological changes in CLL patients who received alemtuzumab as first-line 
therapy and compared the results with fludarabine-based combination therapy. Except for 
CMV, there was no increased incidence of virus reactivation compared with the fludarabine + 
cyclophosphamide +/- rituximab treated controls. All reactivations resolved spontaneously. The 
number of significant antivirus IgG decreases or increases did not differ significantly between 
the two treatment groups. 
  
ii 
LIST OF PUBLICATIONS 
 
I. Karlsson C*, Norin S*, Kimby E, Sander B, Porwit MacDonald A, Nilsson 
B, Johansson E, Mellstedt H, Lundin J, Österborg A. Alemtuzumab as first-
line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of 
clinical effects, infectious complications and risk of Richter transformation. 
Leukemia, 2006, 20, 2204-2207.  
II. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory 
autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with 
alemtuzumab (humanized CD52 monoclonal antibody). Leukemia, 2007, 21, 
511-514. 
III. Karlsson C, Lundin J, Kimby E, Kennedy B, Moreton P, Hillmen P, 
Österborg A. Phase II study of subcutaneous alemtuzumab without dose 
escalation in patients with advanced-stage, relapsed chronic lymphocytic 
leukaemia. British Journal of Haematology, 2009, 144, 78-85. 
IV. Rezvany MR, Jeddi-Tehrani M, Karlsson C, Lundin J, Rabbani H, 
Österborg A, Mellstedt H. Reconstitution of the T-cell repertoire following 
treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients 
with B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 
2006, 135, 475-485. 
V. Karlsson C, Dahl H, Lundin J, Rossmann E, Brytting M, Mellstedt H, Linde 
A, Österborg A. Virus reactivations and serology patterns following first-line 
therapy with alemtuzumab or fludarabine-based combination therapy in 
patients with chronic lymphocytic leukaemia. (Submitted). 
*these authors contributed equally 
 
  
iii
LIST OF ABBREVIATIONS 
ADCC 
Ag 
AIG 
AIHA 
alloSCT 
ATM 
β2-MG 
Bcl-2 
BCR 
BM 
CCL 
CD 
CD40L 
CDC 
CDR 
CFAR 
CHOP 
CLL 
CMV 
CpG 
CR 
CXCR4 
D 
DAPK1 
DAT 
DLBCL 
EBMT 
EBNA-1 
EBV 
ECOG 
ELISA 
EMA 
EORTC 
FA 
FACS 
FC 
FCA 
FCO 
Antibody-dependent cell-mediated cytotoxicity 
Antigen 
Autoimmune granulocytopenia 
Autoimmune hemolytic anemia 
Allogeneic stem cell transplantation 
Ataxia telangiectasia-mutated 
β2-microglobulin 
B cell lymphoma 2 
B cell receptor 
Bone marrow 
CC chemokine ligand 
Cluster of differentiation 
CD40 ligand 
Complement-dependent cytotoxicity 
Complementarity-determining region 
Cyclophosphamide/fludarabine/rituximab/alemtuzumab 
Cyclophosphamide, doxorubicin, vincristine, prednisone 
Chronic lymphocytic leukemia 
Cytomegalovirus 
Cytosine-phosphoguanine dinucleotide 
Complete response 
Chemokine receptor type 4 
Diversity 
Death-associated protein kinase 
Direct antiglobulin test 
Diffuse large B cell lymphoma 
European group for Blood and Marrow Transplantation 
Epstein-Barr nuclear antigen-1 
Epstein-Barr virus 
Eastern Cooperative Oncology Group 
Enzyme-linked immunosorbent assay 
European Medicines Agency 
European Organization for Research and Treatment of Cancer 
Fludarabine/alemtuzumab 
Flourescence-activated cell sorting 
Fludarabine/cyclophosphamide 
Fludarabine/cyclophosphamide/alemtuzumab 
Fludarabine/cyclophosphamide/oblimersen 
  
iv 
FCR 
FDA 
FISH 
GC 
GVL 
HHV-6 
HLA 
IF 
IFN 
Ig 
IGHV 
IL 
ITP 
IV 
IVIG 
IWCLL 
J 
LDH 
LDT 
LPD 
LPS 
mAb 
MBL 
MRD 
MZ 
NCI 
NF-κB 
NK cell 
NLC 
OR 
ORR 
OS 
PC 
PCR 
PD 
PFS 
PI3Kδ 
PLL 
PR 
PRCA 
PS 
Fludarabine/cyclophosphamide/rituximab 
Food and Drug Administration 
Fluorescence in situ hybridization 
Germinal center 
Graft-versus-leukemia 
Human herpesvirus 6 
Human leukocyte antigen  
Immunofluorescence 
Interferon 
Immunoglobulin 
Variable regions of the Ig heavy chain 
Interleukin 
Immune thrombocytopenia 
Intravenous 
Intravenous immunoglobulin 
International Workshop on Chronic Lymphocytic Leukemia 
Joining 
Lactate dehydrogenase 
Lymphocyte doubling time 
Lymphoproliferative disorder 
Lipopolysaccharide 
Monoclonal antibody 
Monoclonal B cell lymphocytosis 
Minimal residual disease 
Marginal zone 
National Cancer Institute 
Nuclear factor-κB 
Natural killer cell 
Nurse-like cell 
Overall response 
Overall response rate 
Overall survival 
Proliferation center 
Polymerase chain reaction 
Progressive disease 
Progression-free survival 
Phosphatidylinositol 3-kinase-δ 
Prolymphocytic leukemia 
Partial response 
Pure red cell aplasia 
Performance status 
  
v 
RBC 
RIC 
RS 
SC 
SD 
SHM 
SLL 
SYK 
TCR 
TCR-BV 
TD 
TGF 
TI 
TK 
TNF 
Treg 
V 
VCA 
VZV 
ZAP70 
Red blood cell 
Reduced-intensity conditioning 
Richter´s syndrome 
Subcutaneous 
Stable disease 
Somatic hypermutation 
Small lymphocytic lymphoma 
Spleen tyrosine kinase 
T cell receptor 
T cell receptor B-variable 
T cell-dependent 
Tumor growth factor 
T cell-independent 
Thymidine kinase 
Tumor necrosis factor 
Regulatory T cells 
Variable  
Viral capsid antigen 
Varicella zoster virus 
Zeta-chain-associated protein kinase 70 
 
 
 
  
vi 
CONTENTS 
Abstract...................................................................................................................................................i 
List of publications ............................................................................................................................... ii 
List of abbreviations ........................................................................................................................... iii 
 
1 CHRONIC LYMPHOCYTIC LEUKEMIA...............................................................................1 
1.1 INTRODUCTION........................................................................................................................1 
1.2 EPIDEMIOLOGY........................................................................................................................1 
1.3 ETIOLOGY................................................................................................................................1 
1.4 PATHOGENESIS ........................................................................................................................2 
1.4.1 The normal B cell counterpart ...........................................................................................2 
1.4.2 Monoclonal B cell lymphocytosis.......................................................................................3 
1.4.3 Genomic aberrations and gene mutations (see also 1.7.1).................................................3 
1.4.4 Epigenetic alterations.........................................................................................................4 
1.4.5 Microenvironment ..............................................................................................................4 
1.4.6 Antigens and CLL pathogenesis .........................................................................................5 
1.5 CLINICAL MANIFESTATIONS .....................................................................................................5 
1.6 DIAGNOSIS ...............................................................................................................................6 
1.7 PROGNOSTIC AND PREDICTIVE FACTORS..................................................................................6 
1.7.1 Genomic aberrations and gene mutations (see also 1.4.3).................................................6 
1.7.2 B cell receptor, IGHV mutational status ............................................................................7 
1.7.3 Surrogate markers..............................................................................................................7 
1.7.4 Markers of tumor burden ...................................................................................................8 
2 TREATMENT OF CLL................................................................................................................9 
2.1 TREATMENT INDICATIONS .......................................................................................................9 
2.2 FIRST-LINE THERAPY .............................................................................................................10 
2.2.1 Single-agent chemotherapy ..............................................................................................10 
2.2.2 Monoclonal antibodies .....................................................................................................10 
2.2.3 Combination chemotherapy .............................................................................................11 
2.2.4 Chemoimmunotherapy......................................................................................................12 
2.2.5 Allogeneic stem cell transplantation ................................................................................13 
2.3 SECOND-LINE THERAPY .........................................................................................................13 
2.4 EMERGING THERAPIES ...........................................................................................................15 
2.4.1 Novel antibodies ...............................................................................................................15 
2.4.2 Small molecules................................................................................................................16 
2.4.3 Immunomodulating drugs.................................................................................................17 
3 IMMUNE DEFECTS AND INFECTIONS IN CLL ................................................................18 
3.1 INTRODUCTION ......................................................................................................................18 
3.2 B CELL DEFECTS ....................................................................................................................18 
3.2.1 Hypogammaglobulinemia ................................................................................................18 
3.2.2 Poor response to vaccination ...........................................................................................18 
3.3 T CELL DEFECTS ....................................................................................................................19 
3.4 OTHER IMMUNE DEFECTS ......................................................................................................19 
3.5 INFECTIOUS PROPHYLAXIS.....................................................................................................20 
3.5.1 Antimicrobial prophylaxis ................................................................................................20 
  
vii
3.5.2 Prophylactic immunoglobulins.........................................................................................20 
3.5.3 Vaccinations .....................................................................................................................21 
4 AUTOIMMUNE COMPLICATIONS IN CLL........................................................................22 
4.1 INTRODUCTION ......................................................................................................................22 
4.2 DEFINITIONS ..........................................................................................................................22 
4.3 PATHOGENESIS ......................................................................................................................23 
4.4 RISK FACTORS........................................................................................................................23 
4.5 TREATMENT OF AUTOIMMUNE CYTOPENIA ............................................................................23 
4.5.1 Simple autoimmune cytopenia..........................................................................................24 
4.5.1.1 AIHA.........................................................................................................................................24 
4.5.1.2 ITP.............................................................................................................................................24 
4.5.1.3 PRCA ........................................................................................................................................25 
4.5.1.4 AIG............................................................................................................................................25 
4.5.2 Complex autoimmune cytopenia.......................................................................................25 
4.5.3 Therapy-related autoimmune cytopenia...........................................................................26 
5 RICHTER´S SYNDROME.........................................................................................................27 
5.1 INTRODUCTION ......................................................................................................................27 
5.2 RISK FACTORS........................................................................................................................27 
5.3 CLINICAL PRESENTATION AND DIAGNOSIS .............................................................................28 
5.4 PROGNOSIS AND THERAPY .....................................................................................................29 
6 AIMS OF THE THESIS .............................................................................................................30 
7 MATERIALS AND METHODS................................................................................................31 
8 RESULTS, DISCUSSION AND CONCLUSIONS...................................................................33 
8.1 PAPER I..................................................................................................................................33 
8.2 PAPER II ................................................................................................................................35 
8.3 PAPER III ................................................................................................................................36 
8.4 PAPER IV ................................................................................................................................38 
8.5 PAPER V .................................................................................................................................40 
9 FUTURE PERSPECTIVES .......................................................................................................42 
10 ACKNOWLEDGEMENTS ........................................................................................................45 
11 REFERENCES ............................................................................................................................47 
 
PAPER I-V 
 
 
 

Chronic lymphocytic leukemia  
 
1 
1 CHRONIC LYMPHOCYTIC LEUKEMIA 
1.1 INTRODUCTION 
Chronic lymphocytic leukemia (CLL) is a malignancy characterized by the accumulation 
of small B lymphocytes with a mature appearance in blood, bone marrow, lymph nodes 
or other lymphoid tissues [1]. In the latest WHO classification scheme CLL is considered 
as a mature B cell neoplasm and is not distinguished from small lymphocytic lymphoma 
(SLL) [2]. Although classifications of lymphoid malignancies have historically treated 
lymphomas and leukemias separately, this distinction is now appreciated as artificial [3]. 
CLL is extremely heterogenous in its clinical course, some patients live for decades 
with no need for treatment, whereas others have a rapidly aggressive clinical course with 
no or little response to therapy. During the past decade there have been major advances in 
understanding the pathogenesis of the disease and more efficient treatments have been 
developed. However, despite these advances, CLL remains incurable with standard 
therapies. 
1.2 EPIDEMIOLOGY 
CLL is among the most common lymphoid malignancies, accounting for approximately 
11% of hematologic cancers in the Western world [4]. The annual incidence is 3-5 newly 
diagnosed patients per 100,000 [5], in Sweden this translates into approximately 500 new 
cases each year [6]. The disease is twice as common in males as females. Compared to 
the Whites, the disease is rarer among Blacks and much rarer in Asian/Pacific Islanders 
(75% and 23% that of Whites respectively) [7]. 
CLL is a disease mainly affecting the elderly and the median age at diagnosis is 72 
years [7]. Although approximately three-quarters of all patients are older than 65 years, this 
group of elderly patients is heavily underrepresented in clinical trials [8]. In order to reduce 
the risk of severe side-effects, this imbalance needs to be considered before start of 
treatment, since there is a clear relationship between age and reduced tolerability to more 
intensive regimens [9]. 
1.3 ETIOLOGY 
The etiology of CLL is still unknown. In most cases no obvious risk factor, except age, 
can be identified. However, for patients with a family history of CLL or other lymphoid 
malignancies, there is strong evidence that a genetic component contributes to the 
etiology [10]. Further, by identifying six CLL risk loci, a genome-wide association study 
have provided the first evidence for the existence of common, low-penetrance 
susceptibility, to a hematological malignancy [11]. 
The relationship with several environmental and occupational exposures has been 
investigated and some, but rather weak, associations have been found to; pesticides, 
magnetic fields, farming and animal breeding [12-14]. 
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During the recent years, the hypothesis that an antigen-driven process contributes to 
CLL development has strongly been supported by evolving data concerning the genes 
responsible for B cell antigen specificity, as discussed in the following chapter.  
1.4 PATHOGENESIS 
The understanding of pathological mechanisms including the multiple events that are 
crucial in the transformation, progression and evolution of CLL, has helped to divide the 
disease into subgroups. This has had a profound impact on prognostication and treatment 
and has resulted in improved possibilities for individualized therapy. 
1.4.1 The normal B cell counterpart 
The cellular origin of CLL cells is not finally clarified [1]. However the current 
knowledge supports a derivation from an antigen-experienced B cell. 
The B cell response to antigen (Ag) stimulation is mediated through the B cell receptor 
(BCR) in normal and malignant B cells. Each B cell displays a distinct BCR that is formed 
through variable combinations of variable (V), diversity (D) and joining (J) segments for 
the immunoglobulin (Ig) heavy chain and V and J gene segments for the light chain. In 
addition to the combinatorial diversity of different segments, the B cell repertoire is 
increased by the introduction of somatic hypermutations through the somatic 
hypermutation (SHM) process during the germinal centre (GC) reaction (reviewed in [15]). 
It has been demonstrated that CLL patients can be divided into two, approximately equal 
sized, subgroups characterized by the presence or absence of somatic hypermutation in the 
variable regions of the Ig heavy chain (IGHV) genes of the CLL clones [16-18]. The cut-off 
value underlying this separation with lesser or more than 98% sequence identity is arbitrary 
[19]. The two groups have different clinical course with poorer survival for patients with 
unmutated IGHV genes. 
There is strong evidence that IGHV-mutated CLL cells (mostly) stem from antigen-
experienced post-GC memory B cells [1]. First, when global gene expression profiles of 
CLL cells were compared to naïve, GC, memory and cord blood CD5+ B cells, it was 
shown that IGHV-mutated CLL cells are most similar in their gene expression patterns to 
memory B cells [20]. Second, the frequency of IGHV gene-mutated CLL cells that have 
mutated BCL6 (which is also targeted by the SHM machinery) is the same as the frequency 
of classical post-GC B cells with BCL6 mutations (30%) [21-23]. Third, a subset of CLL 
cells expresses IgG, indicating that these cases derive from class-switched B cells. These 
CLL cells mostly express IgG1 and IgG3 subclasses, which are typical of GC-associated 
class switching [24, 25]. Fourth, it has been shown that IgM+IgD+CD27+ B cells (as 
IGHV-mutated cells are suggested to be derived from) often are clonally related to classical 
class-switched memory B cells and derive from common CG B cell clones [26].  
Surprisingly, there is evidence strongly arguing that IGHV-unmutated CLL cells also 
derive from antigen-experienced B cells that acquire features of memory B cells [1]. First, 
examination of unmutated IGHV CLL cells showed a gene expression pattern that was 
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more similar to post-GC memory B cells than to any other known B cell subset [20]. 
Second, there is evidence that GC reactions generate some memory B cells that lack 
somatic mutations [26]. Third, many IGHV-unmutated CLL cells express poly- and 
autoreactive antibodies [27-29], and the CLL cells show an activated phenotype [30]. 
Despite these findings, several issues regarding the origin of CLL cells with and 
without mutations in the IGHV genes remain. The possibility that the IGHV mutated cells 
might derive from B cells that accumulate SHM in a T cell-independent (TI) immune 
response, that does not involve the GC, or during a primary, Ag-independent BCR 
diversification process is considered [31]. It is also yet to be understood whether the IGHV 
unmutated CLL cells are activated as a part of TI or T cell dependent immune response and 
if they are conventional naïve B cells, CD5+ B cells or marginal zone-like B cells [1]. 
1.4.2 Monoclonal B cell lymphocytosis 
Monoclonal B cell lymphocytosis (MBL) is defined as the presence of a population of 
monoclonal B cells, usually with a CLL phenotype, which comprise fewer than 5.0 ×109 
cells/L with no evidence of tissue involvement [32]. MBL have been detected in 
approximately 3.5% of healthy individuals who have normal or slightly increased 
lymphocyte counts [33]. The occurrence of such clones increases with age and in first-
degree relatives of patients with CLL [33, 34]. 
The hypothesis that CLL is typically preceded by MBL as a precursor state was tested 
in a population-based prospective study using prediagnostic blood samples from patients 
who were subsequently diagnosed with CLL [35]. In 44 of 45 cases MBL preceded CLL, 
indicating that MBL is a precursor state to CLL in virtually all cases. 
Further, MBL clones often carry genetic lesions that are typical for CLL, such as the 
13q14 deletion [36]. This shows that MBL is often not simply an expansion of normal B 
cells, but that the clones have already acquired initial genetic lesions, which are a hallmark 
of a pre-malignant tumor precursor cell. 
Although several key features of MBL support the idea that it is a precursor stage of 
CLL it is important to stress that only a small fraction of MBL will ever progress to CLL, 
as the frequency of MBL is approximately 100-fold higher than the frequency of CLL and 
the risk of requiring treatment for progressive disease is approximately 1% per year [37, 38]. 
1.4.3 Genomic aberrations and gene mutations (see also 1.7.1) 
In a few recurrently affected chromosomal regions, identified by fluorescence in-situ 
hybridization (FISH), approximately 80% of CLL cases show genetic aberrations [39]. 
The most frequent aberrations are deletions in 13q, 11q, or 17p, and trisomy 12. 
Deletion of 13q14 affects two microRNA genes, mir-15a and mir-16-1, which might 
be implicated in the pathogenesis of CLL [40-42]. This is the most frequent aberration in 
early stage CLL (59%) [43]. 
Deletion of 11q22-q23 affects the ataxia telangiectasia-mutated (ATM) gene in almost 
all cases. The ATM protein kinase is a central component of the DNA damage pathway and 
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mediates cellular responses to DNA double-strand breaks. This deletion is more frequently 
found in refractory CLL than in early stage disease, 25% and 10% respectively [1]. ATM 
mutations have been shown to be present in 12% of all patients with CLL and in 
approximately one-third of the cases with a 11q23 deletion [44]. 
Deletion of 17p13 affects the tumor suppressor gene TP53. As with the 11q deletion 
this deletion is also more common in refractory CLL compared to early stage disease, 31% 
and 4% respectively [1]. It has been shown that there is a tight, but not absolute, correlation 
of 17p deletion and TP53 mutation [45].  
Trisomy 12 is present in 10-20% of the cases, with stable incidence in different disease 
phases [1]. The genes involved in the pathogenesis of CLL with trisomy 12 are unknown. 
In contrast to other types of leukemia or B cell lymphomas, recurrent balanced 
translocations are rare in CLL [1]. 
1.4.4 Epigenetic alterations 
As for other cancers, CLL demonstrates DNA methylation aberrations of multiple genes 
that may be affected at a transcriptional level and play an important role in tumorigenesis. 
An analysis of the global methylation profile found that 2.5-8.1% of the cytosine-
phosphoguanine dinucleotide (CpG) islands in CLL samples were aberrantly methylated 
compared with controls. Such methylations are generally associated with stable silencing 
of the associated gene and it was suggested that a portion of these methylation events 
confer a selective advantage to the malignant cells [46]. A strong correlation between 
promoter methylation and transcriptional silencing of certain individual gene promoters, 
such as death-associated protein kinase 1 (DAPK1) and zeta-chain-associated protein 
kinase 70 (ZAP70) has been found [47, 48].  
In contrast to genetic changes, epigenetic alterations in cancer cells can be reversed 
[49] and are therefore an attractive therapeutic target.  
1.4.5 Microenvironment 
In comparison to normal B lymphocytes, CLL cells show prolonged survival in vivo and 
therefore accumulate in peripheral blood, bone marrow and lymphoid organs [50]. On the 
other hand, when CLL cells are cultured, under conditions that support the growth of 
human B cell lines, they rapidly undergo spontaneous apoptosis [51]. This means that 
their apoptosis resistance, rather than being an intrinsic feature of the leukemic cells, 
depends on external signals [50, 52, 53]. However, CLL cells can be rescued from 
apoptosis ex vivo, if co-cultured with bone marrow-derived stromal cells, fibroblasts, 
dendritic cells, nurse-like cells (NLC) or T cells [54-59]. These cells provide a variety of 
survival stimuli for CLL cells, mediated via soluble factors, extracellular matrix 
components, and signals derived from cell-cell contact [60].  
While circulating CLL cells are largely arrested in G0/G1 phase of the cell cycle, a 
small proportion of leukemic lymphocytes divide in the so-called “proliferation centres” 
(PC) [61]. PCs are focal aggregates of variable size found in lymph nodes and to a lesser 
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extent in the bone marrow (BM) [62, 63]. In the PCs, leukemic lymphocytes are in contact 
with numerous CD3+ T cells, most being CD4+ T cells that express CD40 ligand (CD40L) 
and can support the growth of CLL cells through CD40 ligation [61]. This ligation 
synergizes with BCR signaling [64] and in turn induces several anti-apoptotic signaling 
pathways, including survivin [65] and NF-κB [66].  
Further, CLL cells seem not just to act as passive seeds that need to home into the 
appropriate soil but also as active players that create a supportive microenvironment. They, 
after BCR stimulation or exposure to NLCs, secrete chemokines, such as CCL22 [67], 
CCL3, and CCL4 [68, 69], which can attract other supportive cells, such as T cells. This 
indicates the possibility that the CLL microenvironment is created and maintained through 
a dynamic, interactive coevolution between leukemic and normal bystander cells [70].  
1.4.6 Antigens and CLL pathogenesis 
A picture of CLL as an antigen-driven disease is emerging. It has been shown that almost 
30% of CLL patients share BCRs with restricted, quasi-identical Ig-sequences [71]. Thus, 
one in three patients carried a BCR which was almost identical to another unrelated CLL 
patient. These findings are very striking considering the extremely low probability (10-12) 
of co-expression of identical BCRs. 
Studies on CLL antibody/BCR reactivity have gradually provided clues as to which 
antigens it is that are involved in the formation of stereotyped BCR subsets and thereby 
may be involved in tumor development (reviewed by [72]). Examples of such antigens are 
molecular motifs on apoptotic cells (e.g. modified cytoskeletal proteins and oxidation-
specific epitopes) and exogenous bacteria (e.g. Streptococcus pneumoniae polysaccarides). 
Interestingly, molecular evidence for a possible link between Epstein-Barr virus and 
cytomegalovirus persistence and the utilization of a specific BCR gene (IGHV4-34) was 
recently presented [73]. 
The extensive immunoglobulin analysis in CLL has lead to the hypotheses that 
selection by antigen seems to play an important part in the disease development and could 
even influence disease outcome [72]. 
1.5 CLINICAL MANIFESTATIONS 
With the routine of blood testing, the number of CLL patients who are asymptomatic at 
diagnosis has increased to approximately 40%. The remaining 60% present with various 
symptoms, the most common complaint is fatigue, but this is generally not severe [74]. 
Other common features are enlarged lymph nodes or infection susceptibility. 
Splenomegaly may occur, but massive splenomegaly is usually only seen in patients with 
advanced phase disease. Hepatomegaly occurs less frequently than splenomegaly. 
Patients with very advanced disease may experience weight loss, night sweats and 
general malaise. Signs of BM failure, due to progressive BM infiltration in advance stage 
patients, are anemia, thrombocytopenia and neutropenia. Finally, autoimmune 
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phenomena are more common in CLL patients than in other lymphoid malignances and 
autoimmune hemolytic anemia is the most common one (see chapter 4). 
1.6 DIAGNOSIS  
The diagnosis of CLL requires the presence of more than or equal to 5×109/L  
B lymphocytes in the peripheral blood for the duration of at least three months [75]. The 
leukemia cells found in the blood smear are characteristically small, mature lymphocytes 
with a narrow border of cytoplasm and a dense nucleus lacking discernible nucleoli and 
having partially aggregated chromatin. The clonality and phenotype of the circulating B 
lymphocytes needs to be confirmed by flow cytometry. Each clone of leukemia cells is 
restricted to expression of either kappa or lambda Ig light chains [76]. CLL cells 
coexpress the T cell antigen CD5 and B cell surface antigen CD19, CD20, and CD23 
[75]. The levels of surface immunoglobulin, CD20, and CD79b are characteristically low 
compared with those found on normal B cells [76, 77]. 
A bone marrow aspirate or biopsy is not required at diagnosis of CLL. The diagnosis 
can easily be set by analyses of a blood sample.  
1.7 PROGNOSTIC AND PREDICTIVE FACTORS 
Since CLL is extremely heterogeneous in its clinical course it is hard to predict the 
disease-related morbidity and survival for an individual patient at important time points 
like when diagnosis is set or before start of treatment. For a long time the clinical staging 
systems of Rai and Binet, which classify patients according to tumor burden and 
hematopoetic impairment, have been used to stratify patients into different prognostic 
groups [78, 79]. However, there is still significant heterogeneity within the different stage 
groups. During the recent years several prognostic factors, and also one important 
predictive factor, have been identified. 
1.7.1 Genomic aberrations and gene mutations (see also 1.4.3) 
The presence of 17p deletion is predictive of the worst prognosis of CLL, characterized 
by rapid progression of disease and short survival [39]. It is also associated with poor 
response to chemotherapy with a median survival of less than two years from first 
treatment indication with alkylator and purine-analogue-based therapy (reviewed in [80]). 
There is evidence that the efficacy of “biologic” agents such as anti-CD-52 antibody 
alemtuzumab, lenalidomide and flavopiridol is independent of the genetic background of 
the disease [81-84]. Based on this, 17p deletion may be considered a predictive marker for 
non-response to chemotherapy-based treatment as compared to “biologic” agents such as 
alemtuzumab, lenalidomide and flavopiridol [80].  
There are new data suggesting that the clinical behavior of cases with only the TP53 
mutation is very similar to cases with deletion of one allele and mutation of the remaining 
allele (reviewed in [80]). There is a tight, but not absolute, correlation of 17p deletion and 
TP53 mutation. Among CLL cases which had monoallelic 17p13 deletions the majority 
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showed mutations in the remaining TP53 allele (81%), whereas among cases without 
17p13 deletions TP53 mutations were much rarer (4.5%) [45]. However, the proportion of 
patients with TP53 mutation without 17p deletion was higher (18%) in patients with 
fludarabine refractory CLL [85], suggesting that detection of 17p deletion may not be 
sufficient, but that also TP53 mutation analysis might be important to identify all patients 
with a similarly poor prognosis [86]. 
The presence of 11q deletions is associated with extensive lymphadenopathy, rapid 
disease progression and shorter treatment-free and overall survival [39, 81, 87-89]. Notably, 
evidence from a recent clinical trial indicate that immunochemotherapy with FCR might 
overcome the adverse prognostic significance of 11q deletion [90]. 
Trisomy 12 has previously been associated with poor outcome, however this has not 
been confirmed [87, 88]. Finally, the presence of 13q14 deletion as a sole abnormality is 
characterized by a favourable clinical course [39]. 
1.7.2 B cell receptor, IGHV mutational status 
The IGHV mutation status is currently a well recognized prognostic factor in CLL. 
Patients with unmutated IGHV follow an unfavorable course with rapid progression and 
earlier death [17, 18]. However, regardless of mutational status some V-genes in the VDJ 
rearrangement appear to be associated with distinct biological and clinical features. In a 
Swedish study it was shown that the overall survival among patients expressing the 
IGHV3-21 gene was significantly shorter than other mutated cases and similar to the 
unmutated cases, with a median overall survival of 83 months [91]. The role of the IGHV 
mutational status in guiding therapy is currently unresolved [1]. 
1.7.3 Surrogate markers 
As the determination of IGHV mutation status is rather complicated, a search for 
parameters that are strongly correlated with IGHV mutates is ongoing. One such marker 
is the zeta-chain associated protein kinase 70kDa (ZAP70). Several studies have shown a 
strong association of high ZAP70 expression, as measured by fluorescence-activated cell 
sorting (FACS), and unmutated IGHV genes and BCR function [92-94]. However, 
discordance of ZAP70 expression and IGHV mutation status occurred in up to 25% of 
cases [93]. In a recent work, expression of human Fc receptor like molecules (FCRL, also 
analyzed by FACS) showed a strong association with IGHV-status [95]. FCRL2 
demonstrated 94.4 concordance compared with 80.4% for ZAP70, indicating that this 
might be a reliable surrogate marker. 
The expression of the surface marker CD38 is also correlated to IGHV mutation status. 
However, there are some important considerations, such as no consensus about the best cut-
off value and that expression may vary over time [96], limiting the use of this surrogate 
marker.  
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1.7.4  Markers of tumor burden 
Other parameters of disease activity and tumor burden, besides the Rai and Binet clinical 
staging systems, have been shown to be of prognostic relevance. A lymphocyte doubling 
time of 12 month or less identifies patients with poor prognosis [97]. Further, a number of 
serologic parameters such as thymidine kinase (TK) and β2-microglobulin (β2-MG) have 
been shown to provide information on outcome [98, 99].  
In order to help patients and clinicians in decision making as well as facilitate clinical 
research a prognostic normogram including age, β2-MG, absolute lymphocyte count, sex, 
Rai stage and number of involved lymph node groups has been developed [100]. 
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2 TREATMENT OF CLL 
Historically, the goal for treatment of CLL has focused on reducing disease-related 
problems such as symptomatic lymphadenopathy or splenomegaly. Today, with access to 
more effective therapies it is possible to attain a complete response (CR) in a higher 
percentage of patients. However, physicians must select patients carefully when pursuing 
CR as their treatment goal. Risk of higher toxicity generally accompanies regimens that 
produce higher CR rates, making many patients poor candidates for more aggressive 
therapy. Multiple features, including the molecular characteristics of the patient’s disease, 
clinical features of the patient’s disease, characteristics of the patient and the therapy 
needs to be carefully considered before start of treatment. 
The sections below will focus on treatment results mainly obtained in phase III clinical 
trials. 
2.1 TREATMENT INDICATIONS 
Conventional therapy for CLL is noncurative, and the standard care is to treat patients 
only when their disease is symptomatic or progressive. The criteria for active disease, 
defined in the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 
guidelines for patients participating in study protocols [75], forms the basis for 
recommendation of treatment initiation in both clinical trials and in routine practice 
(Table 1). 
 
Table 1. IWCLL criteria for definition of active disease [75].  
Evidence of progressive marrow failure as manifested by the development of, or worsening of, 
anemia and/or thrombocytopenia. 
Massive (i.e., > 6 cm below the left costal margin) or progressive or symptomatic splenomegaly. 
Massive nodes (i.e., > 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy. 
Progressive lymphocytosis with an increase of more than 50% over a 2‐month period or lymphocyte 
doubling time (LDT) < 6 months. 
Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids or other 
standard therapy. 
Constitutional symptoms, dened as any one or more of the following: 
• unintentional weight loss ≥ 10% in the previous 6 months; 
• signicant fatigue (i.e., Eastern Cooperative Oncology Group (ECOG) PS ≥ 2; inability to work 
or perform usual activities); 
• fevers higher 38.0°C for ≥ 2 weeks without other evidence of infection; or 
• night sweats for ≥ 1 month without evidence of infection 
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It should be noted that in patients with initial blood lymphocyte counts of less than 
30×109/L, lymphocyte doubling time (LDT) should not be used as a single parameter to 
determine treatment indication. In general, the absolute lymphocyte count should not be 
used as the sole indicator for treatment. 
Since several studies have showed that the use of alkylating agents in CLL patients 
with early-stage disease does not prolong survival [101-103], “watchful waiting” is 
recommended for those without treatment indication. This often leaves patients feeling that 
they have a serious health problem but that “nothing is being done” to treat it. However, the 
results of ongoing clinical trials investigating early treatment in asymptomatic patients with 
high-risk molecular features may change this practice for selected patient groups. 
2.2 FIRST-LINE THERAPY 
2.2.1 Single-agent chemotherapy 
Monotherapy with alkylating agents has served as initial therapy for CLL for a long time, 
and chlorambucil has been considered as the “gold standard” for several decades [101]. In 
the 1980s treatment with purine analogues was introduced and in the 1990s chlorambucil 
was challenged by fludarabine, the most studied purine analogue in CLL (Table 2). 
Despite higher response rates and a longer duration of remission and progression-free 
survival (PFS) for the fludarabine treated no improvement of overall survival (OS) could 
be demonstrated [104]. However, in a long-time follow-up analysis a survival benefit for 
the fludarabine treated could be shown [105]. An important objection to this and other 
similar studies is that the median age of the study population is below 65 years while 
three-quarters of the total CLL population are older than this age. Based on this 
imbalance the CLL5 study was designed [8]. Here, when patients above 65 years were 
randomized between chlorambucil and fludarabine, no difference in PFS or OS were 
observed (Table 2). This supports that chlorambucil still plays a role in treating frail 
patients, such as elderly with severe comorbidity, because it is convenient as an oral 
agent and has a low toxicity profile.  
Bendamustine, a purine analogue/alkylator hybrid agent, has recently been tested (in 
patients up to 75 years of age) against chlorambucil [106]. The improved efficacy data lead 
to approval by the US Food and Drug Administration (FDA) in 2008 for the treatment of 
CLL (Table 2).  
2.2.2 Monoclonal antibodies 
Alemtuzumab is a recombinant, humanized, monoclonal antibody directed against CD52, 
a cell surface protein highly expressed on most normal and malignant B and T 
lymphocytes [107]. Alemtuzumab is traditionally given through intravenous (IV) infusion, 
which is the only approved route of administration. However, despite preventive 
measures with dosage escalation and premedication schedules, an administration related 
cytokine release syndrome affects most patients [82, 108]. The release of cytokines such as 
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TNFα, INFγ and IL-6 from e.g. natural killer (NK) cells have been related to this 
syndrome [109]. Frequent symptoms are rigors, fever, chills, nausea, vomiting, skin rash 
and urticaria. These adverse effects occur mainly during the first infusion. The intensity 
and frequency of the symptoms usually decrease during subsequent infusions [82, 108].  
Acute administration-related events are less pronounced if alemtuzumab is 
administrated subcutaneously (SC) [81, 110] and despite local injection-site reactions a 
simplified administration schedule without dose-escalation may be used (Paper III).  
Data from SC alemtuzumab studies have demonstrated at least equivalent efficacy 
compared with corresponding IV studies [81, 82, 108, 111] and recent management 
guidelines stated that SC administration may be used instead of IV [112]. 
When tested against chlorambucil, alemtuzumab treatment, as in a previous phase II 
trial [111], resulted in high response rates [82] (Table 2) and these results lead to approval as 
first-line therapy in the United States in 2007. Accumulating data have demonstrated that 
response to alemtuzumab is independent of the status of the high risk prognostic factor 17p 
deletion or TP53 mutation and recent guidelines recommend that this drug should be 
considered as first-line treatment in selected patients, in particular those with 17p deletions 
[112].  
Alemtuzumab treatment requires special infection-related considerations, since the 
antibody causes severe and prolonged lymphocytopenia that may last 6-18 months 
following first-line therapy [113]. Anti-infective prophylaxis treatment and weekly 
monitoring for cytomegalovirus (CMV) are recommended [112]. 
2.2.3  Combination chemotherapy 
The repair of DNA interstrand crosslinks induced by alkylating agents can be prevented 
by the purine analogue fludarabine [114]. This provides a rationale for combining both 
classes of drugs together and the most extensively studied combination chemotherapy 
regimen for CLL is fludarabine plus cyclophosphamide (FC) [115]. Three randomized 
trials have compared fludarabine alone to the FC combination. All three demonstrated 
significantly higher OR, CR and PFS rates for the combination regimen [87, 116, 117]. 
However, no survival benefit were shown, not even in the largest of these studies where 
patients were randomly assigned to chlorambucil (given at higher doses than in previous 
trials) or fludarabine or fludarabine plus cyclophosphamide [87] (Table 2). It was stated 
that the absence of survival difference was related to the effect of second-line treatments 
since patients receiving the less effective treatment first are more likely to respond in the 
second-line situation [87]. 
In a recent randomized phase III trial there was a direct comparison between the two 
purine analogues fludarabine and cladrabine, each combined with cyclophosphamide, as 
first-line therapy against progressive CLL [118]. Both therapies showed to be equally 
effective and safe. 
 Treatment of CLL 
 
12 
2.2.4 Chemoimmunotherapy 
Since preclinical studies showed evidence for a synergy between rituximab and 
fludarabine [119], rituximab combinations with fludarabine-based regimens have been 
investigated in several trials. Recent data from the first randomized trial, FC +/- 
rituximab (FC versus FCR), showed higher OR rate, more CRs and longer median PFS 
for the FCR treated patients [90] (Table 2). Notably, for the first time this study was able 
to demonstrate that a specific first-line treatment for CLL resulted in a significantly 
improved OS. At three years after randomization, 87% were alive in the FCR arm versus 
83% for the FC treated (p=0.01). Importantly, the population in this trial represents a 
selection of fairly young and physically fit patients. As a consequence, results should not 
be generalized to physically unfit and/or elderly patients with CLL. Further, the subgroup 
of patients with 17p deletion had the worst prognosis and there was no significant 
difference in OS between the two treatment arms for the patients with this genetic 
aberration. It has been commented that patients with 17p deletion should be identified 
before treatment and given alternatives to FCR [120]. In 2009 FCR was approved by 
European Medicines Agency (EMA) as first-line CLL treatment. 
In order to validate the place of alemtuzumab in combination with FC a phase III study 
randomized previously untreated patients, less than 65 years old, with advanced CLL 
between FC plus alemtuzumab (FCA) and FCR. However, because of increased toxicity in 
the FCA arm, seven deaths (7/82), the trial was prematurely stopped [121]. Another trial in 
which a lower dose of alemtuzumab is combined with FC, is still actively recruiting 
(HOVON 68). 
 
Table 2. Progress in the first‐line treatment of CLL, phase III clinical trials. 
Reference  Regimen  N  OR, 
% 
CR, 
% 
PFS, 
mo 
Rai (2000) [104] 
 
Chlorambucil 
Fludarabine 
181 
170 
37 
63 
4 
20 
14 
20 
Eichhorst et al (2009) [8]
(elderly patients, > 65) 
Chlorambucil 
Fludarabine 
100 
93 
51 
72 
0 
7 
18 
19 
Knauf (2009) [106]  Chlorambucil 
Bendamustine 
157 
162 
31 
68 
2 
31 
8 
22 
Hillmen (2007) [82]  Chlorambucil 
Alemtuzumab 
148 
149 
55 
83 
2 
24 
12 
15 
Catovsky (2007) [87]  Chlorambucil 
Fludarabine 
FC 
366 
181 
182 
72 
80 
94 
7 
15 
38 
20 
23 
43 
Hallek (2010) [90]  FC 
FCR 
409 
408 
80 
90  
22 
44 
33 
52 
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2.2.5 Allogeneic stem cell transplantation 
The crucial anti-leukemic principle for allogeneic stem cell transplantation (alloSCT) 
appears to be the immune-mediated anti-host activities conferred with the graft. Thus, 
alloSCT represents the initiation of permanently active cellular immune therapy in the 
recipient, thereby providing a treatment modality that is, in a biological sense, completely 
different to any other cytotoxic or immunological therapy [122]. In isolated cases this 
treatment perhaps may be curative. However, due to advanced age, comorbidity and 
indolent clinical course in the majority of CLL patients alloSCT can not be considered as 
a treatment option in most cases.  
To identify situations where alloSCT might be considered as a preferred treatment 
option, the European group for Blood and Marrow Transplantation (EBMT) in 2006 
worked out a consensus on indications for alloSCT in CLL. It was stated that alloSCT is a 
reasonable treatment option for eligible patients with previously treated, poor-risk CLL 
[123] (Table 3). Notably, according to the third EBM criterion alloSCT is indicated as part 
of first-line treatment for patients with 17p deletion and treatment indication. 
 
Table 3. Criteria for poor‐risk disease according to the EBMT CLL transplant consensus [123]. 
• Non‐response or early relapse (within 12 months) after purine analogue‐containing therapy 
• Relapse (within 24 months) after purine analogue combination therapy or treatment of similar 
efficacy 
• TP53 deletion/mutation (del 17p) requiring treatment 
 
The approach of choice is usually reduced-intensity conditioning (RIC). By this shift 
from  previously used myeloablative alloSCT the rate of non-relapse mortality have 
decreased from up to 44% to 15-25%. Efficacy data shows that long-time PFS can be 
achieved in 30-60% of patients by RIC alloSCT [122, 124]. 
2.3 SECOND-LINE THERAPY 
When a patient relapses after first-line therapy, treatment selection depends on several 
factors such as genetic abnormalities within the CLL cells, disease-related manifestations, 
the general health status of the patient, type of initial therapy and the duration of the 
response. The physician has to reinvestigate the patient and consider collected data in 
order to present the best possible treatment/study suggestion for each individual. 
Generally this is an even more complex situation than before first-line treatment making 
it hard to transfer data from clinical studies into clinical praxis. 
The Swedish CLL group has, in its National Guidelines, treatment recommendations 
for the second-line situation [125]. Here, the recommendations are dependent upon three 
main factors; treatment goal (related to patient general health), refractoriness to previous 
treatment and 17p deletion (Figure 1). 
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Figure 1. The Swedish CLL National Guidelines, updated version 2009‐05‐05 [125]. 
 
Abbreviations: CLL, chronic lymphocytic leukemia; FC, fludarabine and cyclophosphamide; FCR, FC and rituximab; 
A, alemtuzumab; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; FCA, FC and 
alemtuzumab. 
*Refractory disease is defined as treatment failure or disease progression within 6 months to the last 
antileukemic therapy [75]. 
 
The results from a phase III-study, on second-line patients who had been randomized 
between FC and FCR, were recently presented [126]. Data regarding OR, CR and PFS 
were all superior for patients treated with FCR; 70% versus 58%, 24% versus 13% and 
31 versus 21 months, respectively. After a median follow-up time of 25 months there was 
no statistically significant difference in survival between the two treatment arms. 
Notably, only a minority of the patients in this study had previously been exposed to 
fludarabine during their initial therapy. This is a clear limitation since most patients 
today, who are in good physical condition (“go-go” patients), are recommended 
fludarabine-based therapy as first-line treatment [115]. 
Preliminary results from a phase III-study where patients with relapsed or refractory 
CLL were randomized between combination treatment with fludarabine and alemtuzumab 
(FA) or fludarabine single-therapy showed significantly higher OR and CR rates (85% 
versus 68% and 30% versus 16%, respectively) and longer PFS (30 months versus 21 
months) for patients treated with FA [127]. A limiting condition was that only 20% of the 
patients had previously been treated with fludarabine therapy. After a median follow-up of 
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17 months no difference in OS was observed. The rate of infectious complications were 
similar in the two gorups. 
2.4 EMERGING THERAPIES 
Despite advances in treatment, CLL remains incurable with standard therapies. Following 
successive relapses patients become increasingly resistant to treatment, and median 
survival is less than 1 year once patients are fludarabine-refractory [108, 128]. Thus, new 
agents are required and in response to this need several promising investigational agents 
are in clinical development. New agents with at least phase II study data are presented 
below.  
2.4.1 Novel antibodies 
Several second-generation anti-CD20 antibodies are in preclinical and clinical 
development among which ofatumumab has generated the most mature clinical data. 
Ofatumumab is a human monoclonal antibody (mAb) targeting CD20. It binds an 
epitope on the CD20 molecule that is different from that of rituximab. In preclinical 
studies, ofatumumab demonstrated higher affinity for CD20 than rituximab, activated 
complement-dependent cytotoxicity (CDC) more effectively, and was superior to rituximab 
in killing B cell lines with low CD20 expression [129]. 
In a pivotal single-arm study, CLL patients with fludarabine- and alemtuzumab-
refractory CLL (FA-ref, n=59) or with fludarabine-refractory CLL with bulky (> 5 cm) 
lymphadenopathy (BF-ref, n=79) were treated with ofatumumab as single-agent therapy 
[130]. For the FA-ref group OR, PFS and OS was 58%, 6 months and 14 months, 
respectively, and 47%, 6 months and 15 months in the FA-ref group, respectively. 
Importantly, similar response rates were seen irrespective of prior exposure to rituximab-
containing treatments and also irrespective of refractoriness to FCR treatment, a standard 
regimen in earlier lines of CLL therapy. Ofatumumab was approved by FDA in 2009 for 
treatment of CLL that is refractory to fludarabine and alemtuzumab. 
Lumiliximab is a genetically engineered (macacue variable regions, human constant 
regions) mAb targeting CD23, a transmembrane glycoprotein. CLL cells exhibit high 
expression of CD23, while non-CLL cells only minimally express this antigen. In 
preclinical studies, lumiliximab was shown to enhance the effects of fludarabine and 
rituximab [131]. Recently, data from a phase 1/2 study adding lumiliximab to the FCR 
regimen for patients with previously treated CLL were published [132]. The OR rate was 
65%, with 52% of patients achieving a CR, which compares favorably with the CR rate 
previously reported for the FCR regimen alone in relapsed CLL. However, the following 
phase III study failed to show any advantage of the FCR plus lumiliximab combination 
compared to FCR and was prematurely closed [133]. 
A large number of other mAbs are currently in various phases of clinical testing 
against CLL (Figure 2). 
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Figure 2. Antibodies tested against CLL. 
Antibodies indicated in green text have reached approval by FDA and EMA. 
 
2.4.2 Small molecules 
Bcl-2, an antiapoptotic protein is overexpressed in CLL cells and results in resistance to 
chemotherapy. Several compounds affecting the apoptotic resistance mediated via the 
Bcl-2 family have showed activity against CLL. Of which, oblimersen has reached the 
phase III study level. Oblimersen is an antisense oligonucleotide, downregulating the 
Bcl-2 protein. Preclinically, it has demonstrated single-agent activity against CLL cells, 
and potentiated cytotoxic activity of agents such as fludarabine, rituximab, and 
alemtuzumab [134]. In a phase III trial 241 patients who had relapsed after or become 
refractory to fludarabine-based therapy were randomly assigned to FC or FC plus 
oblimersen [134]. The rate of CR/nodularPR was significantly higher for patients treated 
with FC plus oblimersen, 17% versus 7%, respectively. Among patients who achieved 
CR/nodularPR the response duration was significantly longer in the FC plus oblimersen 
arm, however, no significant difference remained if the intention-to-treat populations 
were compared. 
Flavopiridol is a broad cyklin-dependent kinase inhibitor that induces apoptosis of 
CLL cell lines and is not dependent on p53 for its activity. Sixty-four patients with relapsed 
CLL, all previously treated with purine analogue therapy, were treated with single-agent 
flavoperidol [135]. In order to suppress cytokine release syndrome prophylactic 
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dexamethasone was added, this amendment improved treatment tolerability, compliance, 
and response. The rates for OR and CR were 53% and 2% respectively, and median PFS 
for all patients was 9 months. Notably 12 of 21 patients (57%) with 17p deletion 
responded. However, there is a problem with tumor lysis syndrome (TLS) in relation to 
flavopiridol therapy and three patients (5%) required transient hemodialyses with their first 
treatment. 
A variety of other small-molecules are currently investigated in early phase CLL 
studies. 
2.4.3 Immunomodulating drugs 
Lenalidomide is a derivate to thalidomide and belongs to a class of drugs known as 
immunomodulating drugs (IMiDs). Although it has multiple effects on the immune 
system the mechanism of action in CLL treatment is not known. In two phase II trials 
evaluating lenalidomide for treatment of patients with relapsed or refractory CLL, the 
rates for OR and CR were 47% and 32%, respectively, and 9% and 7%, respectively [84, 
136]. Of note, lenalidomide achieved the same OR rate in patients with 11q and 17p 
deletion as in patients without these high-risk abnormalities [136]. Problems with acute 
tumor lysis syndrome and tumor flare reactions were noted among the adverse effects. 
Lenalidomide is currently being tested in 3 ongoing phase III trials in CLL. 
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3 IMMUNE DEFECTS AND INFECTIONS IN CLL 
3.1 INTRODUCTION 
Patients with CLL are all to a degree immunodeficient and infections are the major cause 
of death in between 25-50% of the individuals [137, 138]. This is mediated through 
impairment in humoral and cellular immunity inherent to the primary disease and in the 
further immunosuppression related to the treatment. Bacterial infection of the respiratory 
tract, skin or urinary tract is the most common problem [137] and the most frequent 
pathogens are Staphylococcus aureus, Streptococcus pneumonia, Haemophilus influenza, 
Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa [139]. However, the 
use of purine analogues such as fludarabine, and monoclonal antibodies such as 
alemtuzumab has altered the spectrum of infections. Related to their T cell 
immunosuppressive effects opportunistic infections, like those caused by herpesviruses, 
Pneumocystis, Listeria, mycobacteria, Candida and Aspergillus, may occur [140].  
3.2 B CELL DEFECTS 
3.2.1 Hypogammaglobulinemia 
Hypogammaglobulinemia is the most obvious and well-known CLL-related 
immunodeficiency and is present in up to 85% of patients [138]. The incidence and 
severity of hypogammaglobulinemia is observed to be increased with advanced disease 
stage [141, 142] . All 3 classes (IgG, A, and M) are affected, although predominantly IgG3 
and IgG4 [143]. The mechanisms underlying the decreased immunoglobulin synthesis is 
incompletely understood. A relation to cell-cell contact between plasma cells, which are 
the immunoglobulin-producing cells, and the malignant B cells and release of inhibitory 
cytokines by the latter have been suggested [143]. In vitro studies have shown suppression 
of IgG secretion to be secondary to inhibition by autologous CLL cells, dependent on 
cellular contact and proportional to the number of malignant B cells added. A role of the 
interaction between the Fas ligand (CD95L) on CLL cells and CD95 on plasma cells 
resulting in plasma cell apoptosis was demonstrated [144]. However, this has not been 
replicated by other groups and it seems more likely that the immunodeficiency stems 
from the interaction between B cells and T cells [137]. There is a direct correlation 
between low levels of IgG and the frequency and severity of bacterial infections, most 
commonly Streptococcus pneumonia and Haemophilus influenza [143]. 
3.2.2 Poor response to vaccination 
Vaccination studies have demonstrated that overall antibody responses to vaccines in 
CLL patients are weak [145]. Protein vaccines have produced weak to moderate responses 
in up to 50% of patients, chiefly in early-stage patients with normal serum 
immunoglobulin levels, but responses to polysaccharide vaccines have been virtually 
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zero [146]. So far, there are no data regarding the efficacy of vaccination in preventing 
actual infections or their impact on survival. 
3.3 T CELL DEFECTS 
In most patients with CLL, T cell numbers are increased. This increase mainly affects 
CD8+ cells but CD4+ cells are also increased, though the CD4/CD8 ratio is reversed. It 
was also found that the T cell receptor (TCR) repertoire was skewed [147]. To elucidate 
the basis for the CD8+ T cell expansion in CLL the composition of the T cell 
compartment was investigated [148]. It was shown that the absolute numbers of CD3+ T 
cells was related to expansion of the CD8+ T cell population with a CD45RA+CD27- 
cytotoxic phenotype and that the expansion of these cells was related to CMV infection. 
Repeated antigenic stimulation in vivo as induced by chronic viral infections such as 
CMV was suggested as responsible for the disturbed balance in the composition of T 
cells. 
Changes in normal CD4+ and CD8+ T cells can also be induced by CLL cells via 
direct cell-cell contact and soluble factors, in particular inhibitory cytokines such as IL-6, 
IL-10, TNF and TGF-β [149, 150]. These interactions induces a state of relative T cell 
anergy with poor responses in mixed lymphocyte reactions, poor delayed hypersensitivity 
reactions, Th2 polarization and reduced expression of CD154 [137]. 
Further, it has been shown that CLL patients have significantly increased number of 
CD4+CD25hi regulatory T cells (Treg cells) [151]. Normally these cells play a central role in 
the maintenance of peripheral tolerance by suppression of autoreactive T cell populations. 
Whether the increase in Treg cells in CLL patients contributes to the immune deficiency is 
unclear. 
3.4 OTHER IMMUNE DEFECTS 
Natural killer (NK) cell function is impaired in CLL patients. It has been found that, in 
contrast to normal controls, most of the patients are deficient in the azurophilic 
cytoplasmic granules that are thought to play a role in NK-mediated lysis [152]. 
Overexpression of human leukocyte antigen G (HLA-G), which counteracts the cellular 
immune response of T- and NK cells by several pathways, have in CLL patients shown to 
correlate with the degree of immunosuppression [153]. Neutrophils and monocytes have 
also shown to be defective in their phagocytic and bactericidal function as well as in 
migration and chemotaxis [154]. Finally, levels of different components of the 
complement pathway have been shown to be reduced and accompanied by aberrant 
activation and binding. These abnormalities were correlating with the stage of disease 
and were shown to be present in all patients with advanced disease [155].  
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3.5 INFECTIOUS PROPHYLAXIS  
3.5.1 Antimicrobial prophylaxis 
There are no standard guidelines for antimicrobial prophylaxis in CLL patients, and in 
general, most recommendations for these agents are derived from clinical trials and 
anecdotal reports [140]. Since fludarabine and alemtuzumab are highly 
immunosuppressive and frequently used, infection prophylaxis recommendations in 
relation to treatments including these agents are very important. Based on experiences 
from 92 patients with indolent lymphoid malignancies treated with fludarabine-
containing combination therapy a model with six identified risk factors; age > 60, ≥ 3 
previous therapies, previous fludarabine exposure, time from diagnosis to concurrent 
treatment > 3 years, performance status ≥ 2, and baseline ANC < 2.0 ×109/L, was 
developed [156]. Compared with patients with 0-2 risk factors, patients with ≥ 3 risk 
factors had higher infections rates, more grade 4 neutropenia, and more neutropenic 
septicemia. This model could be used to identify the population most appropriate for 
infection prophylactic treatment. However, when cyclophosphamide is added to 
fludarabine-based therapy (FC, FCR), the use of herpes virus prophylaxis with acyclovir 
and Pneumocystis jirovecii propylaxis with cotrimoxazole (or pentamidine inhalations, 
for cotrimoxazole–allergic patients) during and for 6 months after end of therapy, is 
common. Regarding recommendations for patients receiving alemtuzumab there are 
newly published guidelines recommending herpes virus and Pneumocystic prophylaxis 
treatments, see above, combined with mandatory weekly monitoring for CMV 
reactivation by quantitative PCR (during alemtuzumab therapy) for all patients [112]. 
3.5.2 Prophylactic immunoglobulins 
The use of prophylactic intravenous immunoglobulin (IVIG) is controversial. Several 
clinical trials have demonstrated that it reduces the incidence of mild and moderate 
bacterial infections but none have shown a decrease in mortality [137]. Notably, the IVIG 
treatment does not restore deficiencies of IgM or IgA, low levels of which are implicated 
risk factors for infection. One study estimated that the cost of one quality adjusted life 
year was 6 million USD and concluded that prophylactic IVIG is extraordinary expensive 
in comparison with other treatments generally considered as cost effective [157].  
In the Swedish CLL National Guidelines gammaglobulin prophylactic treatment is 
recommended for patients with serious and/or recurrent bacterial infections and a 
demonstrated hyopgammaglobulinemia with IgG concentration below the normal range 
[125]. Since low dose of IVIG showed to be efficient [158] a dose of 10g every three weeks 
is recommended. As an alternative, subcutaneous immunoglobulin therapy is mentioned. 
This approach over time does provide stable IgG levels and appears to provide adequate 
infection prophylaxis in patients with primary antibody deficiency syndromes [159] . 
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3.5.3 Vaccinations 
There are no formal vaccination guidelines for CLL patients, pneumococcal and seasonal 
influenza vaccines are generally used [140]. Vaccination with live attenuated organisms 
should be avoided [137] because they may cause severe infections in immuncompromised 
individuals like CLL-patients. 
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4 AUTOIMMUNE COMPLICATIONS IN CLL 
4.1 INTRODUCTION 
Although autoimmune complications have been recognized as a complication of CLL for 
a long time, there are limited data on epidemiology, incidence and prevalence. However, 
recent studies suggest that the overall risk of autoimmune complications in CLL is 
approximately 5-10% (reviewed in [160]). Autoimmune hemolytic anemia (AIHA) is the 
most common autoimmune complication with a frequency of 5-10%. The reported risk 
for immune thrombocytopenia (ITP) and pure red cell aplasia (PRCA) ranges from 1-5% 
and about 1% respectively. Finally, autoimmune granulocytopenia (AIG) occur as a rare 
autoimmune cytopenia in CLL patients. 
Non-hematological autoimmune complications of CLL such as paraneoplastic 
pemphigus, glomerulonephritis, C1 esterase deficiency and pernicious anemia are rare 
(reviewed in [160] ) and will not be discussed in the following text. 
4.2 DEFINITIONS 
Strict diagnostic criteria for the CLL related autoimmune cytopenias are lacking. The 
diagnosis of AIHA is usually based on the following laboratory findings: normocytic or 
macrocytic anemia, reticulocytosis, low serum haptoglobin levels, elevated lactate 
dehydrogenase (LDH) level, increased indirect bilirubin level, and a positive direct 
antiglobulin test (DAT) with a broad spectrum antibody against immunoglobulin and 
complement [161]. Two main types of AIHA have been described and are defined 
according to the serologic characteristics of the autoantibodies. In warm-antibody AIHA, 
autoantibodies attach to and initiate the destruction of erythrocytes at temperatures of 
normal body temperature. In cold AIHA, autoantibodies become most active and attack 
erythrocytes only at temperatures well below normal body temperature. Warm AIHA is 
the type most commonly associated with CLL and accounts for about 90% of cases [162, 
163]. For ITP the diagnostic criteria are less clear, and the platelet autoantibody tests lack 
sensitivity and specificity [143]. However, the occurrence of a rapid and deep 
“unexplained” fall in the platelet count, together with some adjuvant conditions, such as 
platelet rise after therapy with corticosteroids or high-dose intravenous immunoglobulins 
(IVIG), an augmented number of megacaryocytes in the bone marrow, or the absence of 
hypersplensim, have been used for ITP diagnosis in several reports [164]. In PRCA, 
examination of the bone marrow to assess the absence of hemopoietic precursors is 
essential and there is an absolute reticulocytopenia [143]. Diagnosis of AIG requires a BM 
study to evaluate neutrophil production and eliminate other possible causes [160]. 
Analyses for the detection of granulocyte-specific antibodies are used [165]. 
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4.3 PATHOGENESIS 
Autoimmune cytopenia affecting CLL patients is usually caused by polyclonal T cell 
dependent mechanisms that result from the loss of self-tolerance. In approximately 90% 
of cases of AIHA and ITP pathogenic high-affinity IgG antibodies directed against red 
blood cell (RBC) or platelet antigens are produced by non-malignant B cells (reviewed in 
[160]). These antibodies can ligate antigens on RBC and platelets and the opsonised cells 
are then destroyed via an ADCC mechanism mediated predominantly by macrophages in 
the spleen and liver [166]. In less than 10% of the autoimmune cytopenia cases the auto-
antibodies are produced by CLL cells. In these cases the autoantibodies are monoclonal 
and usually of IgM-type directed against the I antigen causing AIHA by both 
complement-dependent cytotoxicity and ADCC (reviewed in [160]). In PRCA and AIG 
the autoimmune mechanisms are less well defined. 
4.4 RISK FACTORS 
Risk factors classically associated with autoimmune cytopenia are; male sex, older age, a 
high blood lymphocyte count and advanced disease [162, 164, 167, 168]. An association has 
also been found to unfavorable biomarkers including unmutated IGHV genes, high 
expression of CD38 or ZAP-70 and increased β2-MG [167]. 
In patients with AIHA, over 90% are positive for DAT [162, 163]. In the largest 
prospective trial in CLL to examine the incidence and prognostic impact of a positive DAT 
and AIHA in patients requiring therapy, there was a randomization between chlorambucil, 
fludarabine or fludarabine plus cyclophosphamide (FC) [169]. The incidence of DAT 
positivity for this population of previously untreated patients at study entry was 14% of 
which 28% developed AIHA in relation to therapy. DAT negativity, on the other hand, was 
a strong predictor (> 90%) for not developing AIHA after therapy. The association between 
CLL treatment and autoimmune cytopenia has been recognised since long and in this study 
patients treated with chlorambucil or fludarabine were more than twice as likely to develop 
AIHA as those receiving FC, the latter had a 5% incidence of AIHA, a level that is 
comparable with a 6.5% incidence reported after FCR treatment [170]. It was suggested that 
the FC combination might have a protective effect against the development of AIHA [169]. 
This, in contrast to fludarabine monotherapy, which was not just related to an increased 
incidence of AIHA, but also, to a more severe AIHA clinical course. However, in two other 
studies comparing F and FC there were no statistically significant difference in risk of 
developing AIHA [116, 117]. 
4.5 TREATMENT OF AUTOIMMUNE CYTOPENIA 
The level of evidence regarding treatment recommendations for autoimmune cytopenias 
is not high [161]. Prospective randomized trials are lacking. The situation is also 
complicated by different level of concurrent CLL activity/severity and possible relation 
between the autoimmune cytopenia and previous treatment. Considering the latter 
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problems patients may be categorized into three groups; simple, complex and treatment 
related autoimmune cytopenia [160].  
4.5.1 Simple autoimmune cytopenia 
These patients have autoimmune cytopenia requiring treatment, but without signs of 
active CLL requiring antitumor therapy. In general these patients can be managed with 
therapies similar to those used to treat primary autoimmune cytopenias. 
4.5.1.1 AIHA 
In the Swedish CLL National Guidelines [125] single treatment with prednisolone is 
recommended as first-line therapy. The mechanism of action of corticosteroids in the 
treatment of autoimmune cytopenias is not fully understood. At least two mechanisms 
seems to be involved, i.e., decreased sequestration of RBCs in the spleen and decreased 
autoantibody synthesis [171]. Most patients respond rapidly to treatment, however, 
durable responses are only achieved in about one-third of patients (reviewed by [160]). 
Rituximab has shown promising results as a therapeutic option against AIHA. How 
rituximab works in this situation is not fully understood. Depletion of B cells involved in 
antigen presentation, as well as, production of pathogenic autoantibodies has been 
discussed [172]. In a report on 14 patients treated with rituximab as second- or third-line 
therapy against CLL-related AIHA a response rate of 71% (10/14) was demonstrated, 3 
patients reached CR [172]. 
In order to remove the primary site of red-cell trapping and destruction patients may be 
considered for splenectomy. Substantial data from studies on patients with CLL and simple 
autoimmune cytopenia are lacking. However, in a retrospective evaluation of 30 patients 
with DAT positive AIHA who underwent splenectomy patients with no associated 
systemic disease were separated. In this group splenectomy was an effective treatment 
approach, 11/12 patients responded [173]. 
High doses of IVIG may be effective against AIHA [174]. The blocking of RBC 
sequestration by macrophages is believed to be involved in the mechanism of action [175]. 
The response duration is usually short, however, IVIG treatment may stabilize patients with 
severe and poorly tolerated hemolyses i.e. before RBC transfusion and/or splenectomy. 
For patients not responding to steroids or having AIHA recurrence on steroid 
withdrawal, the use of immunosuppressive drugs such as cyclosporine A, azathioprine, or 
low-dose cyclophosphamide is an option [75].  
4.5.1.2 ITP 
As in AIHA, corticosteroids are recommended as first-line therapy against ITP [125] and 
for about one-third of patients this treatment will be the only treatment required [163]. For 
responding patients who require long-term immunosuppression, immunosuppressive 
drugs such as cyclosporine A, azathioprine, or low-dose cyclophosphamide can be used 
as “corticosteroid-sparing agents” [160]. Splenectomy is traditionally considered as the 
Autoimmune complications in CLL  
 
25
second-line treatment for relapsed ITP and up to 70% of patients may have a long-time 
response after surgery [143, 164]. 
Rituximab have shown promising efficacy in this condition. In a retrospective study on 
89 patients with chronic ITP refractory to several treatments a response rate of 55% was 
reached [176]. Case-report data indicate that alemtuzumab may be a good alternative for the 
treatment of CLL-related ITP not responding to conventional therapy [177].  
4.5.1.3 PRCA 
The treatment approach is the same as for AIHA and treatment response can be 
monitored by assessing the reticulocyte count [143]. There are conflicting data from case 
reports regarding the efficacy of rituximab against PRCA [165, 178]. This may be related 
to the hypothesis that T cells are important in the pathophysiology of this condition [165].  
4.5.1.4 AIG 
The experience regarding management of this CLL-complication is limited. 
Immunosuppression is rarely effective, however spontaneous recovery is possible and it 
is important to support patients with appropriate infection treatment [163]. 
4.5.2 Complex autoimmune cytopenia 
Patients with complex autoimmune cytopenia suffer from autoimmune cytopenia and 
progressive CLL simultaneously. Monotherapy with purine analogues and alkylating 
agents should be avoided in this situation. These therapies are known to increase the risk 
for autoimmune complications in CLL patients, and nucleoside analogues are 
additionally related to an increased risk of more severe autoimmune cytopenias [169, 179-
181]. There are data suggesting that combination therapy including purine analogues such 
as FC [169], FCR [170] and pentostatin plus cyclophosphamide and rituximab (PCR) [182] 
do not increase the risk of autoimmune cytopenia, however, there are no data to support 
the use of these regimens in patients with active autoimmune cytopenia.  
Optimal therapy for complex autoimmune cytopenia would selectively suppress the 
autoimmune cytopenia, be toxic to CLL cells and have a low risk of exacerbating the 
autoimmune process. Such a therapy has not yet been established. However, interesting 
data from two retrospective reports with similar chemoimmunotherapy combinations 
consisting of rituximab, cyclophosphamide, vincristine and prednisone (R-CVP) and 
rituximab, cyclophosphamide and dexamethasone (RCD), respectively, were recently 
published [183, 184]. Both studies showed high response rates against autoimmune 
cytopenia (R-CVP 19/20, RCD 7/7). Importantly, eighteen of the R-CVP treated patients 
had previously been treated for autoimmune cytopenia compared to none of the RCD 
treated. Despite high response rates, response duration was suboptimal both regarding 
autoimmune cytopenia (median time to next treatment for R-CVP was 22 months, median 
response duration for RCD was 26 months) and CLL (median time to next treatment for R-
CVP was 28 months, not reported for RCD). 
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Interestingly, in this difficult situation, single-agent treatment with alemtuzumab has 
shown efficiency (Paper II, [185, 186]) and may be considered for early use in patients with 
complex autoimmune cytopenia. 
4.5.3 Therapy-related autoimmune cytopenia 
This refers to patients developing autoimmune cytopenia during or within 6-12 months of 
treatment for progressive CLL. Those who had a sufficient response to their CLL 
treatment can be treated for their autoimmune cytopenia using the same modalities used 
for “simple” autoimmune cytopenia [160].  
 By the same reasons as mentioned in the text about complex autoimmune cytopenia, 
therapy with purine analogues or monotherapy with alkylating agents are not recommended 
in this situation.  
Although their suboptimal response duration, RCD, R-CVP or high-dose 
methylprednisolone and rituximab have been mentioned as safe therapeutical options for 
patients with therapy-related autoimmune cytopenia [160].  
As in complex autoimmune cytopenia, single-agent alemtuzumab has, in small series 
of patients and case-reports, shown efficacy in therapy-related autoimmune cytopenia 
(Paper II, [110, 185, 187, 188]). 
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5 RICHTER´S SYNDROME  
5.1 INTRODUCTION 
The term Richter´s syndrome (RS) was introduced in 1964 [189] and named after Maurice 
N. Richter who in 1928 described the simultaneous occurrence of a “reticulum-cell 
sarcoma” and CLL [190]. Initially the definition was restricted to the development of a 
large-cell lymphoma in a patient with preexisting CLL. Although the broad definition of 
RS subsequently included other lymphoid malignancies that develop in patients with 
CLL, such as Hodgkin´s disease, prolymphocytic leukemia (PLL), lymphoblastic 
lymphoma and hairy cell leukemia, classical RS describes the progression of CLL/SLL to 
diffuse large B cell lymphoma (DLBCL) [191]. 
CLL transforms to RS in 2.2-16.2% cases [192] at a median time from CLL diagnosis 
of 23-48 months and with DLBCL as the most common subtype [193, 194]. A major factor 
affecting the variability in the RS transformation risk and the time from CLL diagnosis to 
RS is the heterogeneity in biopsy policies among different institutions. This can be 
exemplified by a study, which had a clearly defined and intensive biopsy policy, who 
demonstrated a high rate of RS and short time from CLL diagnosis, 16.2% and 23 months 
respectively [193]. The clonal relatedness of CLL and RS have been investigated by 
characterization of the immunoglobulin heavy and light chain gene rearrangements and 
approximately two-thirds of cases are evolved from the initial CLL clone, the remainder 
consisted of independent second malignancies [195]. 
5.2 RISK FACTORS 
Despite the abundance of biological markers available for predicting CLL progression, 
only few have been shown to be useful to RS prediction. In a consecutive series of 185 
previously untreated CLL cases lymph node size ≥ 3 cm was identified as the sole 
clinical risk factor of RS [193]. In the same study CD38 expression, IGHV4-39 usage and 
absence of del13q were identified as independent risk factors of transformation. 
However, in an observational cohort study using the Mayo Clinic CLL Database no 
statistically significant association was observed between risk of second 
lymphoproliferative disorder (LPD) and CD38, ZAP-70, IGVH mutation status or 
cytogenetic abnormalities among 962 CLL patients [196].  
CD38 has a genetic polymorphism, characterized by a C > G variation in the 
regulatory region of intron 1. A study investigating the distribution of CD38 alleles in 
248 CLL patients showed that G allele carriers had a significantly higher incidence of 
transformation than CC homozygotes and is was stated that the G allele may represent an 
independent risk factor for RS [197]. In a series of 401 CLL patients telomere length (TL) 
was tested as a risk factor of RS and it was found that the risk of RS was significantly 
higher for patients with shorter telomere length [198].  
Purine analogues are highly immunosuppressive and could possible increase risk of 
RT. Data from 962 CLL patients in the Mayo Clinic CLL Database demonstrated an 
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increased risk of secondary lymphoproliferative disorder (5.2%) in patients treated with 
purine analogues compared with patients who had not received this kind of drugs (1.9%; 
P=0.008) [196]. However, no significantly increased risk was shown in long-term follow-up 
data from 2014 patients with CLL or hairy cell leukemia treated on National Cancer 
Institute (NCI) Group C protocols or in the three-armed prospective multicenter LFR CLL4 
trial where 777 CLL patients were randomized between; fludarabine plus 
cyclophosphamide, fludarabine and chlorambucil [87, 199]. 
Information on the immunosuppressive effect of monoclonal antibodies and the 
development of RS are limited. In a first-line phase III study comparing alemtuzumab 
with chlorambucil no case of RS was reported after a median follow-up of 24.6 months 
[82]. However, longer follow-up time is needed to better investigate the role in RS 
transformation as in the long-term results from a first-line phase II study with FCR 
therapy showing a 2.5% risk of RS at a median follow-up of 6 years [200] or as in our 
study on first-line alemtuzumab and matched historic controls with a 16% and 12% risk 
of RS, respectively, at a median follow up of over 5 years (Paper I). 
5.3 CLINICAL PRESENTATION AND DIAGNOSIS 
Richter´s transformation is characterized by the development of systemic symptoms (e.g., 
fever, weight loss, and/or drenching night sweats), sudden clinical deterioration, and, 
usually, a rapid increase in the size of a lymphoid mass at one site. Bulky retroperitoneal 
adenopathy and massive splenomegaly are common presenting features [201]. Extranodal 
spread may occur in RS and sites of involvement include the central nervous system, eye, 
gastrointestinal system, nose, skin, face, bone and bronchus (reviewed in [202]). Patients 
with Hodgkin´s variant of RS generally present at a more advanced stage than do patients 
with true Hodgkin´s disease [194]. 
The most common laboratory finding is an elevated lactate dehydrogenase (LDH) 
level, a marker of tumor growth. Approximately 80% of patients with transformation to 
diffuse large-cell lymphoma have marked elevations of serum LDH disproportionate to that 
anticipated in uncomplicated CLL in the absence of hemolysis [203]. 
The RS transformation diagnosis requires a histological proof and should be 
distinguished from both CLL progression and CLL refractory to therapy [75]. Surgical 
excision or large incision biopsy is recommended since with fine needle aspiration CLL 
cases with numerous proliferation centers are indistinguishable from diffuse large B cell 
lymphoma (DLBCL) [192]. 
In order to guide decisions on which lymph nodes or masses should undergo tissue 
sampling investigation with 2-18Ffluoro-2deoxy-D-glucose positron emission 
tomography/computed tomography (FDG PET/CT) can be useful. A retrospective study on 
37 CLL patients who had underwent FDG PET/CT showed that this investigation can 
detect Richter transformation to DLBCL with a high sensitivity (91%) and a high negative 
predictive value (97%) [204]. Nine patients had false-positive FDG PET/CT; other 
malignancy (n=3, one case of Hodgkin´s lymphoma), accelerated phase of CLL (n=2), 
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refractory CLL with extensive bone marrow involvement (n=3) or atypical pneumonia 
(n=1) affecting the specificity and positive predictive values, 80% and 53% respectively. 
The role of PET remains a research tool in early detection of RS [96]. 
5.4 PROGNOSIS AND THERAPY 
The clinical outcome of RS is generally poor. An analysis of 130 patients treated with 
chemotherapy, with or without rituximab, over a 30-year period at M.D. Anderson 
Cancer Center (MDACC) demonstrated a median survival of 8 months. From five 
adverse factors predicting shorter survival, identified by multivariate analysis in the same 
study, a RS score was developed to predict an individual patient’s risk of death: Zubrod 
(WHO) performance status of more than 1, LDH levels higher than 1.5 × the upper limit 
of normal, platelet counts lower than 100 × 109 /L, tumor size ≥ 5cm, and more than one 
prior therapy. According to number of presenting risk factors, patients could be assigned 
to one of the following risk groups: low risk (score, 0 or 1); low-intermediate risk (score 
2); high-intermediate risk (score 3); high risk (score 4 or 5). Despite this division, the 
median survival in the low-risk group was only 1.12 years [205]. 
There is no consensus on the best therapeutic approach for RS patients [96]. Regimens 
that have been utilized for classical RS treatment reflect the evolution of therapy observed 
in the last few years in the treatment of aggressive NHL. The role of treatment 
combinations containing rituximab was retrospectively evaluated in the case-control study 
from MDACC [205]. Combinations of rituximab with Hyper-CVXD (a fractionated 
cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone regimen) 
variants or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) induced 
responses in 47% of patients compared with a 34% response rate seen with chemotherapy 
alone (P = 0.2). Notably, the number of patients treated with chemotherapy and rituximab 
combinations (n = 47) compared with those treated with chemotherapy alone (n = 79) was 
relatively small and a further study with a larger sample size was suggested. 
OFAR (oxaliplatin, fludarabine, cytarabine and rituximab) is a regimen of 
immunochemotherapy specifically devised for patients with RS or refractory CLL. Twenty 
patients with RS were enrolled in a phase I / II trial with increasing doses of oxaliplatin. 
The response rate was 50% and the 6-month survival rate was 59%. The median response 
duration for the whole study population, including 30 fludarabine-refractory CLL patients, 
was 10 months [206]. 
Allogeneic stem cell transplantation (alloSCT) is a therapeutic option for selected 
patients with RS. In seven patients from the MDACC-study who received alloSCT after a 
CR, CRu, or PR there was a 3-year estimated cumulative survival of 75% [205].  
The role of radiation therapy is generally palliative because RS is dissiminated at the 
time of diagnosis [191].  
Patients with the Hodgkin´s transformation of CLL usually respond to standard 
therapies for Hodgkin´s disease [191].  
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6 AIMS OF THE THESIS 
I. To conduct a long-term follow-up of clinical effects, infectious complications and 
risk of Richter transformation in CLL patients who received alemtuzumab as first-
line treatment. 
 
II. To study the effect of alemtuzumab for the treatment of severe, refractory 
autoimmune hemolytic anemia in CLL patients. 
 
III. To evaluate type, severity and duration of side-effects as well as efficacy of 
subcutaneous alemtuzumab, without dose-escalation, in advanced-stage relapsed 
CLL patients and to prospectively analyze if careful selection of patients can lead to 
increased overall efficacy. 
 
IV. To analyze the T cell repertoire following first-line alemtuzumab treatment in CLL 
patients. 
 
V. To study virus reactivation and serology patterns following first-line alemtuzumab 
treatment in CLL patients. 
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7 MATERIALS AND METHODS 
This research project is based partly (Paper I, IV, V) on our phase II trial of 
alemtuzumab given to previously untreated but symptomatic CLL patients [111] in 
which trial the majority of patients achieved clinical remissions but also severe 
depletion of T cells [113].  
Response evaluation at end of CLL therapy (Paper I, II, III, V) was performed using 
the NCI-IWCLL response criteria [207]. 
 
Paper I. The Swedish Cancer Registry was used to identify matched historical control 
patients. Threehundred fifty-one patients with CLL, diagnosed during the period 1990-
1997 at four hospitals in Stockholm, were identified. Seventy-five of these patients 
matched the inclusion criteria of the phase II trial [111], but had recieved other first-line 
treatments, and were included as controls. The above mentioned time interval was 
choosen to reduce bias related to inclusion in the alemtuzumab study, which started 
1997. Data were collected through a detailed case record review. The two-sided Chi-
square test was used to test differences in proportions. The Wilcoxon´s Gehan exact test 
was used to test differences between curves representing time to treatment failure 
(TTTF) or time to Richter transformation. 
 
Paper II. Patients with severe refractory autoimmune hemolytic anemia (AIHA) were 
recruited and treated at Karolinska University Hospital Solna. All known cases with 
CLL and AIHA at the Department of Hematology, treated with alemtuzumab, were 
included. AIHA response was defined as the elimination of the need for red blood cell 
transfusions and a ≥ 2.0 g/dl rise in Hb concentration independent of transfusions. 
 
Paper III. Patients were recruited at three centers, one in Sweden and two in United 
Kingdom. Consecutive patients who met the inclusion criteria were recruited. However, 
since it had previously been noted that efficacy in patients with bulky disease was less 
marked [208], no such patient was included, although this was not a exclusion criteria.  
Based on the experiences of the injection site reactions from the first-line SC study 
[111] a new subscale, to assess erythema and oedema in detail, was invented by the 
investigators. Additionally, monitoring of subjective adverse events was conducted by 
patients at 6-12 hour intervals using a diary. Objective skin reactions were graded by a 
trained and experienced health care professional every 24-48 hour until completely 
resolved. For statistical analysis of differences in lokal skin reactions Binominal test was 
used. 
 
Paper IV. Blood samples, systematically stored before and during alemtuzumab 
treatment, as well as during long-term follow-up, from five patients from the phase II 
study [111], were investigated. The analyses were restricted to this reduced number of 
patiens due to limitations in the number of frozen blood samples and the extremely 
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labour-intensive techniques applied. T cell receptor B-variable (TCR-BV) gene usage in 
CD4 and CD8 T cells was assessed, by real-time PCR, as well as complementary-
determining region 3 (CDR)-length polymorphism, before and after therapy. The relative 
changes and the expression diversity (number of peaks) in B-variable gene expression 
comparing pretreatment (T0) and post-treatment (T1, T2, T3, …) for each patient were 
assessed by the two-tailed Wilcoxon signed rank test. Comparison of peak numbers for 
all patients at T0 and T1 was performed using the Mann-Whitney U-test. 
 
Paper V. Systematically stored blood samples, from the phase II study patients (n=18) 
[111] and from consecutive control patients (n=27) treated with fludarabine-based 
combination therapy at three centers in Stockholm, were investigated. The number of 
alemtuzumab treated patients was reduced due to limitations in the number of frozen 
blood samples. The laboratory virus and serological analyses, from samples taken 
before, during and after therapy, were done at the Swedish Institute for infectious 
Disease Control in Solna. Quantitative real time PCR was used to detect and measure the 
presence of CMV, EBV and HHV-6. Qualitative real time PCR was used for Parvovirus 
B19 detection. The presence of serum immunoglobulin G (IgG) antibodies against 
CMV, VZV, morbillivirus and Epstein-Barr nuclear antigen-1 (EBNA-1) protein of EBV 
were detected by enzyme-linked immunosorbent assay (ELISA) and against EBV viral 
capsid antigen (VCA) IgG by immunofluorescence (IF). Fisher exact test (two-tailed) or 
Chi-square test was utilized for comparison of the incidence of virus reactivations, 
changes of IgG levels and adverse events in the two treatment groups. For comparison of 
different cell counts between the two treatment groups and between two subgroups of 
alemtuzumab treated (with and without virus reactivation), nonparametric independent 
Mann-Whitney signed-rank test was used. All statistical tests were two-sided. 
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8 RESULTS, DISCUSSION AND CONCLUSIONS 
8.1 PAPER I 
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: 
long-term follow-up of clinical effects, infectious complications and risk of 
Richter transformation 
(Karlsson et al, Leukemia 2006;20:2204-2207) 
 
A long-term follow-up of a phase II study on CLL patients who received alemtuzumab as 
first-line therapy was conducted. The following variables were studied; time to 
progression, time to treatment failure (TTTF), incidence of early and late infectious 
complications as well as frequency of and time to Richter transformation. The results 
were compared with consecutive matched historic controls who had been treated with 
other first-line treatment regimens. 
The median follow-up time from the start of first-line therapy was, for the 38 evaluable 
alemtuzumab-treated and the 75 control patients, 64 (13-102) and 61 (4-132) months, 
respectively. The median TTTF for all alemtuzumab-treated patients was 28 months. 
Among these, 33 were responders and their median TTTF was 32 months. Seven patients 
reached CR and had the longest median TTTF, 77 months. In the control group the median 
TTTF was 17 months (p=0.07 versus alemtuzumab). 
During therapy, no grade 4 infectious complications were observed in the 
alemtuzumab group. Grade 3 infections were observed in four patients (10%) and consisted 
of cytomegalovirus (CMV) reactivation that caused fever without pneumonitis in three 
patients and one Pneumocystis jiroveci pneumonia (in a patient with no prophylaxis due to 
allergy to cotrimoxazole). In the matched controls, grade 3 or 4 infections were observed 
during first-line treatment in 14 patients (19%) and included; fever of unknown origin 
(n=5), pneumonia (n=4, one fatal), septicemia (n=2), CMV (n=1), herpes zoster (n=1), 
dental infection (n=1) and skin infection (n=1). The difference in incidence of infections 
between alemtuzumab-treated patients and controls was statistically not significant. 
During long-term unmaintained follow-up, 7/38 alemtuzumab-treated patients (18%) 
experienced totally 10 episodes of reversible grade 3 infections. No grade 4 or fatal 
infection was observed. In the control group, for which the median TTTF was shorter, the 
incidence of grade 3 or 4 infections was 8/75 (11%). The difference was statistically not 
significant. 
Sixteen percent (6/38) of the alemtuzumab-treated patiens developed Richter 
transformation. The corresponding incidence for the controls was 12% (9/75, not 
significant). The median time from CLL diagnosis to transformation was 44 months (range, 
20-75) for patients treated with alemtuzumab, and 41 months (range, 14-94) for the 
matched historical controls. The median time from the start of CLL therapy to diagnosis of 
transformation was 16 months (range, 3-32 months) in the six alemtuzumab-treated 
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patients and 36 months (range, 1-84 months) in the nine matched historical controls (not 
significant). 
The current work represents the first study of long-term follow-up of patients who have 
received first-line therapy with alemtuzumab for CLL. In the absense of randomized trials, 
retrospective historic comparisons may provide meaningful preliminary information with 
proper considerations. Despite a high proportion of patients with advanced stage disease, a 
significantly higher overall response rate was observed in the alemtuzumab group than in 
the historical control group (p=0.01). Notably, our data on response rate, PFS and TTTF for 
the alemtuzumab treated patients were almost identical as for the CLL patients (n=147) 
randomized to the alemtuzumab arm in a subsequent first-line multi-center phase III trial, 
CAM307 [82].  
It is also important to compare the incidences of CMV reactivation and its 
consequenses to alemtuzumab treated patients in our study and in the CAM307 study. In 
the latter trial patients were tested for CMV during therapy by weekly PCR, in contrast to 
our patients who where only tested if they were symptomatic. The systematic screening in 
the CAM307 trial lead to the detection of positive CMV PCR results in 77 (52%) 
asymptomatic patients and 23 (16%) symptomatic patients. Six (4% of all alemtuzumab 
treated) of the asymptomatic patients with positive CMV PCR were admitted to hospital for 
treatment with IV ganciclovir, and this was recorded as grade 3 events. Among the 
symptomatic patients six (4% of all alemtuzumab treated) were recorded as grade 3 events. 
In our study three (8%) symptomatic grade 3 CMV-reactivations were recorded. In both 
studies all grade 3 reactivations resolved on antiviral treatment. Taken together, our 
strategy, i.e. CMV testing with PCR only if early symptoms occur, instead of weekly 
monitoring, seems reasonable. In Paper V the incidence and clinical relevance of 
subclinical virus reactivations are further investigated.  
The incidense of Richter transformation/development of Richter´s syndrome (RS) was 
high among both the alemtuzumab-treated and the matched historic controls in our study, 
16% and 12% respectively. This might partly be explained by the circumstances that all 
patients had active disease with treatment indication and a relatively long follow-up time of 
64 and 61 months, respectively. Further, a larger proportion of patients treated with 
alemtuzumab in our studypopulation had advanced disease, Rai stage III-IV, compared 
with historic controls, patients included in CAM307 and other studies [209]. However, an 
increased incidence of RS, related to the immunosuppressive effect of alemtuzumab can 
not be excluded. Although data from CAM307, showing no case of transformation after a 
median follow-up of 24 months, does not indicate such a risk. A long-term analysis of the 
randomized CAM307 study is still pending. 
In conclusion, this long-term follow-up of our previously reported efficacy data [111] 
demonstrated, despite severe and long-lasting T cell suppression, that alemtuzumab therapy 
appears to be safe as first-line therapy, with comparable rates of infectious complications 
and incidence of Richter transformation as for matched controls. 
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8.2 PAPER II 
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic 
lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal 
antibody) 
(Karlsson et al, Leukemia 2007;21:511-514) 
 
This is a report on the effect of alemtuzumab treatment on severe, multi-agent refractory 
CLL-related autoimmune hemolytic anemia (AIHA). 
Five patients with advanced CLL, all with severe transfusion-dependent AIHA, 
resistant to conventional therapy, received alemtuzumab at the standard dose. All 5 patients 
responded with a ≥ 2.0 g/dl rise in hemoglobin (Hb) concentration, in the absence of further 
transfusions, after a median time of 5 weeks (range, 4-7 weeks). The mean Hb increased 
from 7.2 g/dl at baseline to 11.9 at end of treatment. All patients remained stable , without 
further AIHA episodes, after a median unmaintained follow-up time of 12 months with a 
mean Hb of 12.5 g/dl. Clinical responses (as defined by NCI criteria [207]) were seen in 4 
patients (when the study was published one was still on therapy and response data were not 
available) of which three reached a CR.  
AIHA is a frequent and serious complication in patients with CLL [160]. Before 
treatment is initiated the level of concurrent CLL activity/severity and possible relation 
between the AIHA and previous treatment has to be considered. Addressing this, a 
categorisation of patients with autoimmune cytopenia into three groups have been 
suggested [160]. Thus, AIHA may be defined as simple, complex or therapy-related. 
All five patients in our report may be categorised as being affected by both complex 
and therapy-related AIHA. They had progressive CLL and AIHA concomitantly and, 
additionally, had received treatment for progressive CLL within 6-12 months. This is a 
challenging situation with no established treatment recommendations. However, 
alemtuzumab, with a well documented antitumor efficacy [112] and profound 
immunosuppressive activity [113], constitutes a potential therapeutic option. 
All patients responded with elimination of AIHA and a marked increase in hemoglobin 
concentrations. In parallel, CLL responses were achieved in all but one patient. 
In conclusion, the results from this report suggest that alemtuzumab may be highly 
effective in the treatment of severe AIHA in patients with progressive CLL who have failed 
to respond to conventional immunosuppressive therapy, such as corticosteroids, 
splenectomy, rituximab and chemotherapy. 
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8.3 PAPER III 
Phase II study of subcutaneous alemtuzumab without dose escalation in patients 
with advanced-stage, relapsed chronic lymphocytic leukaemia 
(Karlsson et al, British Journal of Haematology 2009;144:78-85) 
 
A phase II study was conducted evaluating the type, severity and duration of side-effects 
as well as efficacy of subcutaneous (SC) alemtuzumab, without dose-escalation, in 
advanced-stage relapsed CLL patients. Alemtuzumab 30 and 3 mg was administered SC 
simultaneously, in opposite thighs, day 1, followed by 30 mg three times per week. 
The first doses of 30 mg and 3 mg produced injection-site-reactions (all but one were 
grade 1/2) in 13/20 and 9/20 patients, respectively. The second dose on day 3 resulted in 
skin-reactions in 10/20 patients and the third, fourth, fifth and sixth injection produced 
reactions in 6/20, 1/20, 2/20 and 0/20 patients, respectively. Mild “flu-like” symptoms 
occurred during week 1 in 10/20 patients. All side-effects had subsided by the sixth dose. 
15/20 patients (75%) responded (12 partial responses, three complete responses) with a 
median time to treatment failure (TTTF) of 20 months. 
Intravenous administration is still a frequently used (and the only approved) route of 
delivering alemtuzumab to patients with CLL [82, 108]. However, one study in previously 
untreated CLL patients [111], and one study in fludarabine-refractory CLL patients [81], 
have suggested that SC injection may result in a marked reduction of the “first-dose” flu-
like reactions that frequently occur after IV administration. SC injections may induce 
transient skin reactions, which in previously untreated patients may sometimes be quite 
extensive [111].  
Our findings have demonstrated that patients with previously treated, advanced-phase 
CLL can be treated with the maximum dose of alemtuzumab 30 mg SC upfront without 
unacceptable toxicity. Local skin reactions at the injection site were generally of grade 1 or 
2 and transient, and appeared to be less intense than those seen with SC alemtuzumab as 
first-line therapy in patients with CLL [111]. Even though the first alemtuzumab 30 mg SC 
injection resulted in slightly more injection-site reactions than the 3 mg SC control 
injection (65% versus 45%), most skin symptoms had subsided within 2 days, and the 
reactions induced by continued alemtuzumab administration were less intense and of 
shorter duration.  
Furthermore, by upfront careful selection of patients, a high overall response rate 
(ORR) (75%) and long TTTF (median 20 months for responding patients) was obtained, 
even though all but three patients had relapsed after, or were refractory to, purine analogue-
based therapy and 60% of the patients had Rai stage III or IV disease. One possible major 
reason for the high response rate may be that only patients with WHO performance status 
(PS) grade 0 or 1 were recruited as it has previously been suggested that a good PS is 
closely linked to successful therapeutic outcome with alemtuzumab [210]. Another and 
possibly linked explanation for the high ORR in our study may be that most patients 
completed therapy as planned; the median length of therapy was 12 weeks. Finally, none of 
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the patients had bulky lymph nodes, i.e. ≥ 5 cm, which also contributed to the high ORR. 
Established effective treatments for CLL patients with bulky lymph nodes who have failed 
purine analogue-based therapy are currently lacking. 
In conclusion, a starting dose of 30 mg SC was well tolerated. The SC route of 
administration for alemtuzumab may confer major advantages once the injection skin 
reactions have subsided, both in terms of practical aspects for the patients as well as the 
burden on health care providers. Our results also suggested that optimal selection of 
advanced-phase CLL patients for alemtuzumab therapy may result in a high response rate 
and durable remissions, the results can be regarded as preliminary only due to the small 
size of our study (n=20). Important success factors, to be confirmed in extended trials, may 
be a good performance status, absence of bulky lymph nodes, and avoidance of early 
discontinuation of planned therapy by appropriate management of predictable toxicities. 
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8.4 PAPER IV 
Reconstitution of the T-cell repertoire following treatment with alemtuzumab 
(anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic 
leukaemia  
(Rezvany et al, British Journal of Haematology 2006;135:475-485) 
 
In this pilot study, T cell receptor B-variable (TCR-BV) gene usage in CD4 and CD8 T 
cells was assessed by real-time PCR, as well as complementarity-determining region 3 
(CDR3)-length polymorphism. Analyzes were performed on samples taken before and 
after first-line alemtuzumab therapy, in five patients with CLL. 
A decline in expression of most BV family genes in both CD4 and CD8 T cells was 
observed after alemtuzumab treatment, which was followed by a gradual increase in most 
BV families during long-term follow-up. After treatment, CDR3-length polymorphism 
showed an even more restricted pattern in CD4 T cells compared with pretreatment, with a 
shift towards a monoclonal/oligoclonal pattern. The clonally restricted pattern was 
significantly reduced in CD4 (P < 0.01) but not in CD8 T cells. This was followed by a 
gradual increase in the number of peaks within the CDR3 region of the different TCR-BV 
families, i.e. a polyclonal repertoire, during long-term follow-up. 
Despite being clinically effective, concerns were raised in early trials with regard to the 
risk of infections associated with alemtuzumab therapy in heavily pretreated patients with 
advanced B cell malignancies [211, 212]. The introduction of valaciclovir and 
cotrimoxazole prophylaxis resulted in significant reduction, but not elimination, of the risk 
of serious infections [81, 82, 108, 111, 213-215]. Further, because of an increased risk of 
CMV reactivation, recent alemtuzumab management guidelines recommend weekly 
monitoring for CMV reactivation during therapy [112]. 
It has been recommended that the length of anti-infective prophylaxis should be based 
on the actual number of CD4 T cells, and that such prophylactic treatment should be 
continued until the CD4 T cell count exceeds 0.2 × 109 cells/L [216]. However, this 
recommendation does not take into account the recovery pattern of the complex elements 
of the T cell immune system (repertoire in particular) following alemtuzumab treatment. 
In this pilot study, we analyzed in depth the usage and clonality patterns of TCR-BV 
gene families in CD4 and CD8 T cells before and after first-line treatment with 
alemtuzumab in CLL patients. The TCR-BV pattern and T cell recovery during follow-up 
were different in CD4 T cells compared with CD8 T cells. CD4 T cells showed a more 
clonal/oligoclonal pattern than CD8 T cells shortly after treatment compared with 
pretreatment. Because a broad CD4 T cell repertoire is mandatory for protective immunity 
against various pathogens [217], it is likely that the highly restricted repertoire, as described 
here, along with low total numbers of CD4 T cells, contributes significantly to the 
increased frequency of viral (i.e. CMV) and opportunistic infections that may occour 
during and after alemtuzumab therapy [218]. Our finding, that the T cell repertoire 
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normalised during long-term follow-up corresponded to the very few late infections 
observed in our patients [219]. 
In conclusion, these results indicate that perturbations of the T cell repertoire following 
alemtuzumab are complex and not reflected by changes in the total number of CD4/CD8 T 
cells only. The restricted CDR3 pattern present prior to therapy became even more 
restricted after treatment, followed by a normalisation of CD4 repertoire during long-term 
follow-up. 
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8.5 PAPER V 
Virus reactivations and serology patterns following first-line therapy with 
alemtuzumab or fludarabine-based combination therapy in patients with 
chronic lymphocytic leukaemia 
(Karlsson C et al, Submitted) 
 
In this study we systematically investigated the incidence and clinical relevance of 
subclinical virus reactivations and serological changes in CLL patients who received 
alemtuzumab as first-line therapy [111], then compared the results with those of patients 
who received fludarabine-based combination therapy.  
Virus reactivations were rare, but significantly more common in alemtuzumab-treated 
patients; 6/440 analyses were positive versus 0/455 (P < 0.05) and 6/18 patients had at least 
one virus reactivation versus 0/27 (P < 0.01). No significant difference remained when 
CMV was excluded from the comparison. All virus reactivations resolved spontaneously. 
Alemtuzumab-treated patients with virus reactivation had significantly higher lymphocyte 
subset counts (P < 0.01 - < 0.05) at end of treatment than those without virus reactivation. 
Sixteen of the 18 alemtuzumab-treated patients were evaluable with regard to 
differences in the IgG levels between baseline, end of treatment and 6-12 months post-
therapy, except for EBV p107 IgG analysis, which included samples from 15 patients. 
Seventeen of the fludarabine combination-treated patients had their serology results 
evaluated in the same way as the alemtuzumab-treated patients. A significant decrease of at 
least one IgG titre was observed in 4/16 and 3/17 of the patients, respectively (not 
significant). Increasing titres were observed in some patients.  
Results from this study demonstrate a low but statistically significantly higher 
incidence of virus reactivation in the alemtuzumab group, expressed both as total number 
of reactivations and number of patients with at least one reactivation, compared with the 
fludarabine combination-treated patients irrespectively if the latter were first or later-line 
patients. However, this difference was mainly attributable to CMV and was not significant 
if the other viruses were considered separately. Besides CMV, only one other therapy-
related reactivation – an asymptomatic HHV-6 reactivation at 1 month during therapy – 
was detected, compared with no virus reactivation in the control group. All reactivations 
resolved spontaneously without discontinuation of alemtuzumab therapy. This indicates 
that CMV testing with PCR on symptomatic patients, instead of weekly monitoring, might 
be considered during alemtuzumab monotherapy in the first-line setting at experienced 
centres.  
The incidence of serological changes was higher in the alemtuzumab group, but the 
differences were not significant. However, some titres decreased significantly in up to 25% 
of the patients, which raises the question of whether such patients might need specific 
preventive measures to avoid reinfection in terms of health care contacts and otherwise. 
Especially VZV-infections may become very severe even in healthy adults, and control of 
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serology status, at least after exposure, should be recommended. Notably, decreasing titres 
were also observed in some FC(R) treated patients. However, this study also shows that 
spontaneous recovery of IgG reactivities after alemtuzumab therapy is possible: one patient 
(A8) had four significant decreases of IgG titres, against CMV, VZV, measles and EBV 
p107G. This patient was later included in the control group (C9), and comparison of the 
IgG levels at baseline 1, before alemtuzumab, with levels at baseline 2, before fludarabine 
combination treatment, did not show any remaining significant decrease; the IgG levels had 
spontaneously recovered. Further, the IgG increase in patient (A18) had a clinical correlate, 
a reinfection with VZV 10 months after end of treatment. This patient had very low 
detectable titres at baseline but generated such IgG titres following the infection. 
At end of therapy, the number of analyzed lymphocyte subsets was significantly lower 
in the alemtuzumab group. Interestingly, patients in the alemtuzumab group who had had a 
subclinical virus reactivation had significantly higher amounts of CD4+/CD3+, 
CD8+/CD3+ and CD3+/CD56+ cells at end of therapy, and for CD8+/CD3+ cells also at 8-
12 months post-therapy, compared with patients from the same group without virus 
reactivation. This could correlate to an antiviral immune response and can be related to 
previous findings of expansions of CMV-specific CD8+ and CD4+ T cells in CLL patients 
[148, 220]. 
In conclusion, except for CMV, there was no increased incidence of subclinical or 
clinical virus reactivation following first-line SC alemtuzumab compared with the FC(R)-
treated controls. All reactivations resolved spontaneously, indicating that CMV testing with 
PCR on symptomatic patients, instead of weekly monitoring, might be considered during 
alemtuzumab monotherapy in the first-line setting at experienced centres. The number of 
significant antivirus IgG decreases or increases did not differ significantly between the two 
treatment groups; however, the titre decreases noted in individual patients raises the 
question of whether such patients might need special infection-preventive measures to 
avoid reinfection. Patients ability to respond with titre and lymphocyte subset increases 
following clinical infection as described in this paper suggest that vaccination could be 
successful if proper vaccines/adjuvants are used. 
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9 FUTURE PERSPECTIVES 
The evolution of new therapeutic options for CLL patients is promising. Monotherapy 
with alemtuzumab has been established in the first-line (selected patients, such as 17p-), 
as well as, later-line-setting (i.e. fludarabine-refractory disease). The results presented in 
this thesis have provided additional information on: long-term follow-up, efficacy in 
severe multi-agent refractory complex AIHA, simplified SC route of administration and 
in-depth analysis of immunological effects and its clinical consequences. However, 
several issues remain to be elucidated. 
In pharmacokinetic studies, high alemtuzumab concentrations have been correlated to 
improved clinical responses [221-223] and it has been hypothesized that optimized treatment 
could be better achieved if alemtuzumab administration was based on serum levels [223]. 
This approach could possibly help to individualize alemtuzumab therapy and needs to be 
further investigated, in particular in relation to safety when the tumor burden is low. 
Several strategies to achieve minimal residual disease (MRD)-free status by 
incorporating alemtuzumab into the approach have been evaluated, hypothesizing that this 
may translate into longer remission duration and survival [214, 222-225]. However, a major 
concern for the use of alemtuzumab as consolidation therapy is infections [214, 215]. To 
decrease toxicity and increase efficacy, new strategies for alemtuzumab consolidation 
therapy have to be developed. 
Alemtuzumab still lacks an effective and safe “partner” for optimal combination 
therapy. In combination with FC, alemtuzumab have been associated with increased 
toxicity and such therapy is not recommended outside clinical studies [112]. In an ongoing 
first-line phase III study for biological high-risk CLL, patients are randomized between FC 
+/- alemtuzumab therapy (HOVON 68). The use of a relatively low alemtuzumab dose and 
selection of high-risk patients performed in this trial may hopefully result in a better 
outcome than what was seen in a previous study which was prematurely stopped because of 
increased toxicity in the FC plus alemtuzumab arm [121]. Interestingly, fludarabine plus 
alemtuzumab (in the absence of cyclophosphamide) was equally safe as fludarabine mono-
therapy in a phase III trial [127]. 
In one phase II trial, combination therapy with alemtuzumab and rituximab has been 
tested as first-line CLL treatment [226]. Early data on 24 patients demonstrated a high ORR 
and CR rate, 92% and 79%, respectively. The promising data on the new anti-CD20 
antibody, ofatumumab, makes this antibody, potentially, an even better combination 
candidate [130]. Theoretically, the alemtuzumab and ofatumumab combination could be a 
suitable alternative for CLL patients with severe BM failure, concomitant autoimmune 
cytopenia or 17p deletion, i.e. patients, in whom current chemotherapy-based combination 
treatments are either too toxic or ineffective. This will be explored in a up-coming study. 
In a small series of patients with p53 defects and bulky lymphadenopathy, high-dose 
methylprednisolone in combination with alemtuzumab has shown promising results. This 
will be evaluated more thoroughly within the NCRI UKCLL06 trial [227]. The 
Future perspectives  
 
43 
immunomodulatory agent lenalidomide is another potential partner. Its effects on the 
immune system may result in synergistic effects when combined with alemtuzumab. 
Further, both lenalidomide and alemtuzumab have shown efficacy in CLL with 17p 
deletion making the combination especially interesting for this subgroup of patients. Our 
research group has currently a phase I/II study on the combination of alemtuzumab and 
lenalidomide in chemorefractory CLL patients. 
Kinases have become effective targets for cancer treatment, especially in chronic 
myelogenous leukemia (CML). In recent years, kinases have been identified that are 
potential targets in CLL treatment as well, e.g. spleen tyrosine kinase (SYK) and 
phosphatidylinositol 3-kinase-δ (PI3Kδ) [228]. Ror-1 is another potential target as the 
receptor contains a tyrosine kinase domain [229]. New in vitro data on CAL-101, a selective 
PI3Kδ inhibitor, indicate that this might be a suitable drug to combine with alemtuzumab 
[230]. CAL-101 promoted apoptosis in CLL cells, independently of common prognostic 
markers (including deletion 17p). Further, it was demonstrated that this agent greatly 
decreases the production of several inflammatory cytokines and it was speculated that this 
effect might diminish the antibody related infusion toxicity (cytokine release syndrome). It 
was also shown that CAL-101 does not interfere with alemtuzumab-mediated ADCC.  
CXC chemokine receptor type 4 (CXCR4) antagonists may disrupt adhesive 
interactions between bone marrow stromal cells and CLL cells and thereby reduce growth 
and drug-resistance signals to the malignant cells (reviewed in [231]). In vitro studies have 
demonstrated that the addition of CXCR4 antagonists may abrogate the protective effect of 
stroma on CLL cells and thereby increase the sensitivity to alemtuzumab [232]. Thus, the 
addition of CXCR4 antagonists to alemtuzumab therapy could potentially lead to improved 
efficacy by mobilization of less therapy resistant CLL cells from protective niches in bone 
marrow and secondary lymphoid tissues.  
In conclusion, potential candidates for a alemtuzumab “partnership” are not lacking. 
The number of possible clinical trials is constantly increasing. 
The role of alemtuzumab in treatment of autoimmune cytopenia is poorly investigated. 
We have demonstrated efficacy in a small series of patients with progressive CLL and 
AIHA refractory to conventional therapy (Paper II). However, larger series of patients are 
needed as well as formal consensus on the definitions of autoimmune cytopenia treatment 
evaluations [161]. 
The long-term risks of alemtuzumab immunosuppressive effects need to be evaluated 
in a larger series of patients, such as the patients participating in the CAM307 study [82]. 
This would improve the knowledge regarding the risks for development of secondary 
infections and malignancies. We have, in relation to CLL therapy, identified significant 
decreases of specific IgG content in serum (Paper V). Some of these patients might need 
revaccination/vaccination. However, CLL patients have weak antibody responses to 
vaccination [145] and vaccination with live attenuated organisms should, because of risk for 
side effects, be avoided [137]. Thus, development of improved vaccination strategies is 
needed. Notably, it has recently been shown that lenalidomide may augment both cellular 
and humoral responses to pneumococcal vaccination in relapsed myeloma patients [233]. 
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This needs to be investigated also in CLL patients and our research grpup has started to 
explore lenalidomide as an adjuvant in an ongoing CLL antitumor vaccination program. 
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